It is made available under a CC-BY-NC-ND 4.0 International license .

1	Genome-wide analysis of heart failure yields insights into disease
2	heterogeneity and enables prognostic prediction in the Japanese population
3	
4	Authors: Nobuyuki Enzan ¹⁻³ , Kazuo Miyazawa ¹ , Satoshi Koyama ^{1,2,4} , Ryo Kurosawa ¹ , Hirotaka
5	Ieki ^{1,5} , Hiroki Yoshida ^{1,6} , Fumie Takechi ^{1,7} , Masashi Fukuyama ^{1,6} , Ryosuke Osako ^{1,8} , Kohei
6	Tomizuka ⁹ , Xiaoxi Liu ⁹ , Kouichi Ozaki ^{1,10} , Yoshihiro Onouchi ^{1,11} , BioBank Japan Project,
7	Koichi Matsuda ¹² , Yukihide Momozawa ¹³ , Hiroyuki Aburatani ¹⁴ , Yoichiro Kamatani ¹⁵ , Takanori
8	Yamaguchi ⁸ , Akazawa Hiroshi ⁶ , Koichi Node ⁸ , Patrick T. Ellinor ^{2,3,16} , Michael G. Levin ^{17,18} ,
9	Scott M. Damrauer ^{18,19} , Benjamin F. Voight ²⁰⁻²² , Jacob Joseph ^{23,24} , Yan V. Sun ^{25,26} , Chikashi
10	Terao ⁹ , Toshiharu Ninomiya ²⁷ , Issei Komuro ^{28,29} and Kaoru Ito ^{1*}
11	
12	Affiliations:
13	1. Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative
14	Medical Sciences, Yokohama, Japan.
15	2. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.
16	3. Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA,
17	USA.
18	4. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT,
19	Cambridge, MA, USA.
20	5. Department of Genetics, Stanford University School of Medicine, Stanford, USA.
21	6. Department of Cardiovascular Medicine, Graduate School of Medicine, The University of
22	Tokyo, Tokyo, Japan.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 23 7. Department of pediatrics Graduate School of Medical and Pharmaceutical Sciences, Chiba
- 24 University, Chiba, Japan.
- 8. Department of Cardiovascular Medicine, Saga University, Saga, Japan.
- 26 9. Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical
- 27 Sciences, Kanagawa, Japan.
- 10. Medical Genome Center, Research Institute, National Center for Geriatrics and Gerontology,
- 29 Obu, Japan.
- 30 11. Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan.
- 31 12. Laboratory of Clinical Genome Sequencing, Department of Computational Biology and
- 32 Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo,

33 Japan.

- 13. Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences,
- 35 Kanagawa, Japan.
- 14. Genome Science Division, Research Center for Advanced Science and Technology, The
- 37 University of Tokyo, Tokyo, Japan.
- 38 15. Laboratory of Complex Trait Genomics, Department of Computational Biology and Medical
- 39 Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
- 40 16. Demoulas Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, MA,
- 41 USA.
- 42 17. Division of Cardiovascular Medicine, Perelman School of Medicine, University of
- 43 Pennsylvania, Philadelphia, PA, USA.
- 44 18. Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 45 19. Department of Surgery, University of Pennsylvania Perelman School of Medicine,
- 46 Philadelphia, PA, USA.
- 47 20. Department of Genetics, University of Pennsylvania Perelman School of Medicine,
- 48 Philadelphia, PA, USA.
- 49 21. Department of Systems Pharmacology and Translational Therapeutics, University of
- 50 Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
- 51 22. Institute of Translational Medicine and Therapeutics, University of Pennsylvania Perelman
- 52 School of Medicine, Philadelphia, PA, USA.
- 53 23. Veterans Affairs Providence Healthcare System, Providence, RI, USA.
- 54 24. Brown University, Providence, RI, USA.
- 55 25. VA Atlanta Health Care System, Decatur, GA, USA.
- 56 26. Emory University Rollins School of Public Health, Atlanta, GA, USA.
- 57 27. Department of Epidemiology and Public Health, Graduate School of Medical Sciences,
- 58 Kyushu University.
- 59 28. Department of Frontier Cardiovascular Science, Graduate School of Medicine, The
- 60 University of Tokyo, Tokyo, Japan.
- 61 29. International University of Health and Welfare.
- 62
- 63 Correspondence should be addressed to K.I. (kaoru.ito@riken.jp) and I.K. (komuro-
- 64 tky@umin.ac.jp)

It is made available under a CC-BY-NC-ND 4.0 International license .

65 Abstract:

66	To understand the genetic basis of heart failure (HF) in the Japanese population, we performed
67	genome-wide association studies (GWASs) comprising 16,251 all-cause HF cases, 4,254 HF
68	with reduced ejection fraction cases, 7,154 HF with preserved ejection fraction cases, and 11,122
69	non-ischemic HF cases among 213,828 individuals and identified five novel loci. A subsequent
70	cross-ancestry meta-analysis and multi-trait analysis of the GWAS data identified 19 novel loci
71	in total. Among these susceptibility loci, a common non-coding variant in TTN (rs1484116) was
72	associated with reduced cardiac function and worse long-term mortality. We leveraged the HF
73	meta-GWASs along with cardiac function-related GWASs to develop a polygenic risk score
74	(PRS) for HF. The PRS successfully identified early-onset HF and those with an increased risk
75	of long-term HF mortality. Our results shed light on the shared and distinct genetic basis of HF
76	between Japanese and European populations and improve the clinical value of HF genetics.

It is made available under a CC-BY-NC-ND 4.0 International license .

77 Introduction

Heart failure (HF) is increasing in prevalence and incidence¹. A previous genome-wide 78 association study (GWAS) of all-cause HF identified 47 risk loci². Considering that GWAS of 79 coronary artery disease (CAD) yielded 175 susceptibility loci³ and GWAS of atrial fibrillation 80 (AF) yielded 150 loci⁴, the number of loci for HF was lower than expected even when using 81 82 multi-trait analysis of GWAS (MTAG) that jointly analyzes GWAS summary statistics of 83 multiple related traits, boosting statistical power by leveraging information across traits. This is partly because HF is a heterogeneous syndrome resulting from multiple etiologies. GWAS of HF 84 with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) was 85 performed to address this heterogeneity⁵. This study identified additional susceptibility loci that 86 had not been found in the all-cause HF GWAS. Given this fact, analysis of HF subtypes should 87 be useful to better understand the genetic architecture for HF. On the other hand, since the vast 88 majority of these HF-GWASs have been performed in European populations, the genetic 89 90 pathophysiology of HF in non-European populations is not well understood. Additionally, it is 91 difficult to apply polygenic risk scores (PRSs) derived from such GWASs to non-European populations. 92

Therefore, in the present study, we performed a large-scale Japanese GWAS to explore the genetic architecture of all-cause HF and HF subtypes: HFrEF, HFpEF, and non-ischemic HF (NIHF), followed by a cross-ancestry meta-analysis. Further, we investigated potential causal genes at the identified HF-associated loci by integrating several prioritization methods to characterize the underlying mechanism, clarify the link with cardiomyopathy, and propose genedrug interactions relevant to HF. We also evaluated the impact of common variants in established cardiomyopathy genes on HF phenotypes and long-term mortality. Subsequently, we

It is made available under a CC-BY-NC-ND 4.0 International license .

- 100 identified a *TTN* common variant, which affected HF severity and mortality rate. Additionally,
- 101 we developed a PRS derived from the cross-ancestry meta-analysis of each HF subtype along
- 102 with HF-related phenotypes and demonstrated the ability of the HF-PRS to predict the early
- 103 onset of HF and stratify the long-term mortality, which may provide evidence for the clinical
- 104 utility of HF-PRS and lay the foundation for the realization of precision medicine in HF.

It is made available under a CC-BY-NC-ND 4.0 International license .

105 **Results**

106 GWAS revealed a Japanese-specific genetic architecture of HF

107	An overview of the study design is shown in Fig. 1. We performed Japanese case-control
108	GWASs to investigate the association of up to 7,974,473 common genetic variants in the
109	autosomes (minor allele frequency (MAF) $> 1\%$) with the risk of four HF phenotypes. 16,251
110	HF cases were identified, including 4,254 cases of HFrEF, 7,154 cases of HFpEF, and 11,122
111	cases of NIHF (Fig. 1). Cases of all-cause HF, HFrEF, and HFpEF were compared with 197,577
112	controls. For the NIHF analysis, CAD cases were excluded from control samples, and 171,995
113	controls were used. Sample overlaps between each HF phenotype are shown in Supplementary
114	Fig. 1a. The mean LV ejection fraction (LVEF) was 48.94% for all-cause HF, 28.74% for
115	HFrEF, 62.08% for HFpEF, and 50.86% for NIHF (Supplementary Table 1). These GWASs
116	identified 18 genome-wide significant loci in total, of which five were previously unreported
117	(Fig. 2a, Supplementary Fig. 1b, Supplementary Fig. 1c, Supplementary Table 2, and
118	Supplementary Datasets). The estimated heritability for each HF phenotype is described in
119	Supplementary Notes 1. We assessed the 62 previously reported HF loci and confirmed that
120	their effects were mostly concordant with our Japanese GWAS (Supplementary Notes 2,
121	Supplementary Fig. 2, Supplementary Table 3). Additionally, while the reproducibility of the
122	novel loci was obtained in both internal and external replications, two of the novel loci were
123	specific to the Japanese population and were not found in Europeans (Supplementary Notes 3,
124	Supplementary Fig. 3a, b, c, d and Supplementary Table 4, 5).
125	To identify HF-associated variants independent of the lead variant at each locus, we

127 5.0×10^{-6}) were additionally detected, increasing the total number of HF-associated signals to 21

It is made available under a CC-BY-NC-ND 4.0 International license .

128	(Supplementary Table 6). Among these, the frequencies of rs893363 (Alternative allele
129	frequency; EAS 96.2% vs. EUR 61.9%, β = -0.167 in NIHF) and rs4307025 (Alternative allele
130	frequency; EAS 73.0% vs. EUR 28.0%, $\beta = 0.0912$ in NIHF) differed significantly between East
131	Asians and Europeans.
132	To assess the pleiotropic effects, we used the lead variant in each locus as a proxy and
133	assessed its effect sizes in Japanese GWAS of cardiovascular-related phenotypes ⁶ . The novel
134	variant rs35593046 found in all-cause HF (β = -0.0630) /NIHF (β = -0.0767) had a protective
135	role against high blood pressure (Supplementary Fig. 4a and Supplementary Table 7). It is the
136	intronic variant of CACNA1D and is much more frequently observed in the East Asian
137	population than in European populations (53.8% vs. 26.8%).
138	
139	Common variants in cardiomyopathy genes were responsible for HF development
140	We then sought to prioritize potential causal genes at the identified HF-associated loci.
141	First, of the 310 variants in LD ($r^2 > 0.8$) with 18 lead variants, 6 missense variants were
142	observed (Supplementary Table 8). Among loci previously reported only in the multi-trait
143	analysis of GWAS (MTAG), we found missense variants rs11718898, rs2305398, and rs3732678
144	in the CAND2 gene, three of which were in high LD. CAND2 has been reported to link mTOR
145	signaling to pathological cell growth leading to cardiac remodeling ⁷ . A missense variant
146	rs2627043 found in the HFrEF GWAS encodes TTN, one of the well-known cardiomyopathy
147	genes. Notably, the allele frequency was much higher in the East Asian population than in
148	European populations (64.7% vs. 20.1%). We also found the East Asian-specific missense
149	variant rs671 encoding ALDH2, which has been reported to be an HF-related variant in the BBJ
150	1 st cohort ⁶ .

It is made available under a CC-BY-NC-ND 4.0 International license .

151	Next, we assessed whether the lead variants we identified were functioning as an
152	expression quantitative trait locus (eQTL) or a splicing quantitative trait locus (sQTL) using
153	GTEx version 8 data. Among the lead variants in novel loci, rs6471480 was found to be an
154	eQTL in subcutaneous adipose tissue (Supplementary Fig. 4c and Supplementary Table 9)
155	and an sQTL in the left atrial appendage (Supplementary Fig. 4d and Supplementary Table
156	10) for the DPY19L4 gene. Additionally, all of the five HFrEF-related variants, previously
157	identified only in MTAG with cardiac measurements ² , were revealed as eQTL in the left
158	ventricle. This result may suggest that MTAG in the previous study conferred additional
159	statistical power to discover these variants by integrating cardiac function-related traits.
160	We conducted gene-based analyses, MAGMA ⁸ and H-MAGMA ⁹ , utilizing promoter
161	capture Hi-C in cardiovascular-related tissues ¹⁰ . Among novel loci, DPY19L4 reached statistical
162	significance (FDR < 0.05) in the aorta and adrenal gland using H-MAGMA but not MAGMA
163	(Supplementary Fig. 4e and Supplementary Table 11-12). Given that the aorta and adrenal
164	gland are known to be involved in the pathophysiology of hypertension, this is consistent with
165	the association of DPY19L4 with the use of a calcium channel blocker, one of the
166	antihypertensive drugs ⁶ .

Furthermore, related to the HF loci identified in our Japanese GWAS, we assessed nearby genes containing variants classified in ClinVar as having pathogenic evidence for HF-relevant monogenic disorders, knock-out mouse phenotype, and known cardiomyopathy genes¹¹. *NEBL*, located within 500kb of the lead variant rs7075837, was reported to harbor pathogenic variants responsible for primary dilated cardiomyopathy according to the ClinVar database (**Supplementary Table 13**). *NEBL* was also one of the known cardiomyopathy genes (**Supplementary Table 14**), and *Nebl* knock-out mice showed dilatation of the left atrium and

It is made available under a CC-BY-NC-ND 4.0 International license .

174	ventricle (Supplementary Table 15). SPRED2 harbors pathogenic variants responsible for
175	Noonan syndrome, which causes hypertrophic cardiomyopathy (Supplementary Table 13).
176	Knock-out of Spred2 also causes dilatation of the heart (Supplementary Table 15). Knock-out
177	of <i>Csmd1</i> showed obesity and abnormal glucose metabolism (Supplementary Table 15).
178	Polygenic Priority Score (PoPS) was recently introduced to estimate responsible genes using
179	various gene features, such as cell-type-specific gene expression and biological pathways. We
180	thus used PoPS to choose the top two likely genes in each locus. As a result, SPRED2 and
181	CSMD1 were also prioritized (Supplementary Table 16).
182	Taken together, DPY19L4, CSMD1, SPRED2, and NEBL were prioritized by at least
183	three out of 10 predictors as Japanese-specific HF-related genes (Fig. 2a, 2b, and
184	Supplementary Table 17). Of note, common variants in cardiomyopathy genes NEBL were also
185	responsible for HF development. NEBL encodes the cardiac Z-disk protein nebulette, and rare
186	variants in this region cause dilated, hypertrophic, and LV non-compaction cardiomyopathy ¹² .
187	DPY19L4 was likely to act on arteries to cause hypertension based on pleiotropic effects and H-
188	MAGMA results. This interpretation was supported by the fact that quercetin, which attenuated
189	atherosclerosis via modulating oxidized LDL-induced endothelial cellular senescence,
190	downregulated DPY19L4 in human aortic endothelial cells ¹³ . Based on knockout phenotypes,
191	<i>CSMD1</i> is likely to cause HF through metabolic disorders, consistent with a previous study ¹⁴ .
192	SPRED2 loss-of-function induced defects in convergence and extension cell movements leading
193	to cardiac defects and Noonan-like syndrome ¹⁵ . Aside from novel loci, AOPEP, previously
194	reported in Japanese all-cause HF GWAS ⁶ , was also associated with HFrEF, HFpEF, and NIHF
195	and the Japanese-specific signal (Supplementary Fig. 5). Given that AOPEP cleaves

It is made available under a CC-BY-NC-ND 4.0 International license .

196	angiotensin I	II to a	ngiotensin	IV a	bioactive	nentide of	the renin.	angiotensin	nathway it is
190	angiotensin i	$\Pi \iota 0 a$	ngiotensin	1v, a		pepude of	une remm	angiotensin	paulway, it is

- 197 likely that *AOPEP* is responsible for HF development through hypertension.
- 198

199 Cross-ancestry meta-analysis identified seven novel loci for HF

- 200 To improve the statistical power to detect further genetic associations with HF, we
- 201 conducted cross-ancestry meta-analyses by combining the current Japanese GWAS (BBJ), along

with European², Chinese¹⁶, American¹⁷, and African² all-cause HF GWAS, European HFrEF and

- 203 HFpEF GWAS⁵, and the UK biobank¹⁸ and FinnGen (data release 9) NIHF GWAS
- 204 (Supplementary Table 18 and Supplementary Notes 4). These analyses identified 58 HF-
- associated loci with genome-wide significance ($P < 5.0 \times 10^{-8}$; Supplementary Fig. 6,

206 Supplementary Fig. 7a, Supplementary Table 19, and Supplementary Datasets). Of these

207 loci, seven have not been reported previously, including one novel locus detected in the current

208 Japanese GWAS (CACNA1D locus). In total, we identified 11 novel loci through the current

209 Japanese GWAS and cross-ancestry meta-analysis.

210 In internal replication, all the newly identified loci were nominally significant both in

East Asian and European populations (Supplementary Fig. 7b and Supplementary Table 20).

212 rs35593046 (CACNA1D), rs7659823 (EDNRA), rs5823966 (ZNF397), and rs1541596 (CARM1)

were much more frequently observed in the East Asian population (Supplementary Fig. 7c and

214 Supplementary Table 20). Replication analyses of three lead variants in HFrEF and HFpEF

using independent datasets showed concordant results with the same effect direction

216 (Supplementary Notes 5, Supplementary Figure 7d, e, and Supplementary Table 21).

It is made available under a CC-BY-NC-ND 4.0 International license .

218 Genes related to arrhythmia, metabolism, and heart morphology were prioritized in the

219 cross-ancestry meta-analyses

220	Of the 1,621 variants in LD ($r^2 > 0.8$) with 75 lead variants in any of the HF subtypes, 10
221	missense variants and one stop-gain variant were observed (Supplementary Table 22). We
222	found an additional missense variant rs2305397 in the CAND2 gene.
223	We performed a transcriptome-wide association study (TWAS) and splicing-TWAS
224	using the identified loci in the cross-ancestry meta-analyses and the GTEx data. Among novel
225	loci, ZNF397 was prioritized in the tibial artery by TWAS (Supplementary Fig. 8a and
226	Supplementary Table 23). As for loci previously found only in MTAG, MTSS1, PROM1, and
227	SPATA24 were prioritized in the left ventricle or left atrial appendage and CCDC136 was
228	prioritized in the tibial artery. The splicing-TWAS showed that ZNF397 (left ventricle) and
229	EDNRA (left ventricle and left atrial appendage) were prioritized among the novel loci
230	(Supplementary Fig. 8b and Supplementary Table 24). TTN, SMARCB1, SPATA24,
231	EFCAB13, CCDC136, CAND2, and CARM1 were prioritized in the left ventricle or left atrial
232	appendage. Gene-based analysis by MAGMA showed that CACNA1D, LHX3, EDNRA, and
233	ZNF397 reached statistical significance (Supplementary Fig. 8c and Supplementary Table
234	S25 and S26).
235	Among the novel loci, no gene harbored pathogenic variants responsible for
236	cardiovascular-related phenotypes according to the ClinVar database (Supplementary Table
237	27). Based on genetic knockout phenotypes in mice, <i>Cacnald</i> deletion caused arrhythmia

- 238 (Supplementary Table 28) and was prioritized by PoPS (Supplementary Table 29). Knockout
- of *Ednra* showed abnormal heart and aortic morphology (**Supplementary Table 28**) partly

It is made available under a CC-BY-NC-ND 4.0 International license .

240	because <i>Ednra</i> was associated with heart development ¹⁹ . Deletion of <i>Carm1</i> caused dilatation of
241	the left atrium, and deletion of <i>Lhx3</i> caused decreased body weight (Supplementary Table 28).
242	In the cross-ancestry meta-analyses, EDNRA, ZNF397, CACNA1D, CARM1, LHX3, and
243	PDE3A were prioritized by at least three predictors (Fig. 2a, 2b, and Supplementary Table 30).
244	Among these six genes, EDNRA and PDE3A were linked to existing medications (refer to
245	Candidate drugs linked to disease susceptibility loci section in the main text). No prioritized
246	gene was found associated with rs10851802 (Supplementary Notes 6).
247	
248	The HF-related common variant in the cardiomyonathy gene MYBPC3 was identified in
240	MTAG
277	
250	To further enhance the statistical power of HF GWAS, we conducted MTAG ²⁰ . First, we
251	assessed the genetic correlation between HF and cardiac MRI parameters for the left ventricle ¹¹ ,
252	left atrium ²¹ , right ventricle, right atrium ²² , left ventricular mass ²³ , and fibrosis ²⁴ . Because left
253	ventricular mass was strongly correlated with HF in all of the HF subtypes (Supplementary Fig.
254	9a and Supplementary Table 31), we integrated HF GWAS and left ventricular mass GWAS by
255	MTAG. We then found an additional eight novel loci (Supplementary Fig. 9b, 9c,
256	Supplementary Table 32, and Supplementary Datasets). Of the 1,597 variants in LD ($r^2 > 0.8$)
257	with 36 lead variants, seven missense variants were observed (Supplementary Table 33).
258	Among the novel loci, rs6265 is a missense variant for BDNF (Supplementary Table 33).
259	TWAS showed that BDNF and ILRUN were prioritized in the left ventricle and atrial appendage,
260	and PLPP3 in the fibroblasts (Supplementary Fig. 10a and Supplementary Table 34).
261	Splicing-TWAS showed that ILRUN (left ventricle and atrial appendage), BDNF (coronary
262	artery/aorta/fibroblasts), and SLC4A7 (fibroblasts) were prioritized (Supplementary Figure 10b

It is made available under a CC-BY-NC-ND 4.0 International license .

and Supplementary Table 35). *SLC4A7*, *MYBPC3*, *BDNF*, and *PCSK1* reached statistical
significance in gene-based analyses (Supplementary Fig. 10c and Supplementary Table 3637).

266	Combined with known Mendelian genes (Supplementary Table 38), mouse phenotypes
267	(Supplementary Table 39), and PoPS (Supplementary Table 40), BDNF, MYBPC3, SLC4A7,
268	ILRUN, PCSK1, PTPRJ, and PLPP3 were prioritized (Fig. 2a, 2b, Supplementary Table 41).
269	Notably, common variants in one of the known cardiomyopathy genes MYBPC3 were
270	responsible for HF development as well as TTN, NEBL and BAG3. Other prioritized genes are
271	described in Supplementary Notes 7.
272	Here, comparing the disease susceptibility loci detected by the Japanese GWAS,
273	European GWAS, cross-ancestry meta-analyses, and MTAG, we found that there were common
274	and different genetic effects between the East Asian and European populations. Among novel
275	loci found in BBJ-specific or cross-ancestry meta-analyses, AOPEP, CSMD1, DPY19L4, and
276	SPRED2 were significant only in the East Asian population (Supplementary Fig. 4 and
277	Supplementary Fig. 11). On the other hand, HLA-B, APOH, CFL2, HSD17B12, UBA7 were
278	European specific loci (Supplementary Fig. 11).
279	
280	Distinct mechanism of each HF phenotype in cross-ancestry analysis

To compare the mechanisms of each HF phenotype, we conducted a pathway analysis and found that cellular senescence, cyclin-dependent kinase-related pathway, miRNAs involved in DNA damage responses, signaling events mediated by prolactin, Tie2 mediated signaling, and Notch signaling pathway were enriched in all-cause HF (**Fig. 3** and **Supplementary Table 42**). Notch signaling was also enriched in NIHF. From a clinical perspective, miRNAs involved in

It is made available under a CC-BY-NC-ND 4.0 International license .

286	DNA damage response may be attractive targets to improve cancer patient outcomes in
287	chemotherapy-related cardiomyopathy, which may be induced by DNA-damaging
288	chemotherapy. The prolactin inhibitor bromocriptine had higher odds of left ventricular function
289	recovery in peripartum cardiomyopathy, one of the leading causes of maternal mortality ²⁵ . Tie2-
290	mediated signaling is not only required for normal vascular development but also is required for
291	ventricular chamber formation ²⁶ . Notch is associated with heart development and regulates
292	cardiac regenerative processes ²⁷ . Aside from cyclin-dependent kinase-related pathways,
293	sarcomere-related pathways including Z-disc, I-band, and actin-binding were enriched in HFrEF
294	(Fig. 3 and Supplementary Table 42). Cardiac cell development/differentiation was enriched in
295	NIHF. On the other hand, no specific pathway was enriched in HFpEF.
296	Additionally, cell type-specific enrichment analysis with gene expression and epigenetic
297	marks showed that H3K4me1 in the fetal heart was enriched in HFrEF, but the other three HF
298	phenotypes did not show any particular cell type enrichment (Supplementary Table 43). Taken
299	together, despite the smaller sample size, HFrEF showed strong enrichment in the heart,
300	especially in the sarcomere.
301	With miRNA enrichment analysis using MIGWAS, HFrEF showed significant
302	enrichment for the miRNA-target gene network (Supplementary Figure 12a). Out of eight
303	candidate miRNA-gene pairs (Supplementary Table 44), HSPB7 was also significant in TWAS
304	analysis (Supplementary Table 34), suggesting that hsa-mir-4728-HSPB7 was the most likely
305	pair. HSPB7 has been reported to be indispensable for heart development and associated with
306	dilated cardiomyopathy ⁴⁷ .

We conducted the cell type-specific analysis at single-cell resolution using scDRS⁴⁸ with healthy, dilated cardiomyopathy, and hypertrophic cardiomyopathy datasets⁴⁹. All four HF

It is made available under a CC-BY-NC-ND 4.0 International license .

309 phenotypes showed significant enrichment for cardiomyocytes (Supplementary Fig 12b and Supplementary Table 45). Additionally, HFpEF showed enrichment for adipocyte and vascular 310 smooth muscle cells^{50, 51}, suggesting that HFpEF may have additional mechanisms beyond the 311 other HF phenotypes. 312 313 314 Candidate drugs linked to disease susceptibility loci We curated drugs from DrugBank²⁸ and Therapeutic Target Database^{29, 30} 315 (Supplementary Fig. 13) for the prioritized genes from the Japanese GWAS, cross-ancestry 316 meta-analyses, and MTAG. Our analysis supports epidemiological evidence that several 317 318 medications cause or exacerbate HF. Given that knockout of CACNA1D, EDNRA, and CDK6 in mice caused abnormal myocardial fiber physiology, abnormal heart ventricle morphology, and 319 decreased myocardial fiber number, respectively, those inhibitors could worsen HF. Indeed, the 320 previous meta-analysis suggested that dihydropyridine calcium channel blockers (nifedipine) can 321 be a risk for HF³¹. The EDNRA inhibitor bosentan caused fluid retention in HF patients³². One of 322 the CDK4/6 inhibitors, palbociclib, was associated with worse outcomes in patients who 323 developed atrial fibrillation or HF³³. All these outcomes were concordant with our genetic 324 325 analyses. Tirzepatide, one of the emerging antidiabetics^{34, 35}, could be a potential drug 326

repositioning candidate through the *GIPR* locus, which had a protective role against HF. As of now, tirzepatide has not been fully evaluated for its effects on cardiovascular outcomes, but at least it did not increase the risk of cardiovascular events³⁶. Currently, a study of tirzepatide in participants with HFpEF (SUMMIT trial) is ongoing (NCT04847557).

331

It is made available under a CC-BY-NC-ND 4.0 International license .

332 A TTN common variant plays an important role in HF outcomes

From the Japanese GWAS and cross-ancestry meta-analyses, we found lead variants 333 associated with cardiomyopathy genes, TTN, NEBL, and BAG3 (Supplementary Table 14). 334 Given the nature of cardiomyopathy genes, we hypothesized that these variants by themselves 335 could affect cardiac function and prognosis. Among those, the risk allele of TTN lead variant 336 337 (rs1484116) was less frequent in the East Asian populations than in European populations (Risk allele frequency: EUR 0.800, EAS 0.315; Fig. 4a) according to the gnomAD database, while we 338 observed the effect size of this variant was higher in Japanese than Europeans (Fig. 4b). First, we 339 340 investigated the association between these variants and cardiac function, and we found that the lead variants of TTN (rs1484116) and BAG3 (rs61870083) were significantly associated with 341 lower left ventricular ejection fraction (TTN, effect size -1.16, 95% confidence interval (95%CI) 342 -1.55 - -0.77, $P = 7.80 \times 10^{-9}$; BAG3, effect size -2.79, 95% CI -3.58 - -2.00, $P = 3.88 \times 10^{-12}$; 343 Fig. 4c). We then repeated the same analysis in NIHF to exclude possible effects of CAD, and it 344 yielded similar results (Fig. 4c). These variants of TTN and BAG3 were also associated with 345 lower LVEF in individuals without known cardiac diseases in UKBB cohorts (Fig. 4c right 346 panel). Furthermore, we assessed the effects of these common variants on long-term HF 347 348 mortality among non-HF subjects and HF subjects. The Kaplan-Meier estimates and Cox regression analysis demonstrated that the TTN lead variant (rs1484116) was significantly 349 associated with worse outcomes in HF patients (HR 1.24, 95% CI 1.06-1.46, $P = 8.12 \times 10^{-3}$; Fig. 350 351 4d and e). These results suggest the importance of the TTN common variant in risk stratification of HF patients and this variant could be a novel potential biomarker for HF. 352 353

354 **Development of a HF-PRS and its performance**

It is made available under a CC-BY-NC-ND 4.0 International license .

355	Although most GWASs have been conducted in European populations, PRSs derived
356	from European GWASs have shown poorer performance in other populations. On the other hand,
357	PRSs derived from cross-ancestry GWASs have been reported to improve their accuracy in
358	understudied populations ³ . Furthermore, integrating not only cross-ancestry GWAS of interest
359	but also related phenotypes (e.g., blood pressure and LDL cholesterol for CAD) has proved to
360	enhance the PRS performance ³⁷ . Here, we split our case-control samples into the derivation
361	dataset, dataset for linear combination, test dataset, and survival analysis dataset to avoid sample
362	overlap (Supplementary Fig. 14). We derived each PRS from the Japanese all-cause HF,
363	European/American/African all-cause HF, and European HFrEF, HFpEF, CAD, AF, and left
364	ventricular mass with PRS-CS (see Methods section). The linear combination of these PRS was
365	performed by Lasso regression with 10-fold cross-validation, resulting in the exclusion of PRSs
366	calculated from Native American all-cause HF, and European NIHF. For the PRS derived from a
367	single population GWAS, as concordant with the population specificity, the PRS derived from
368	BBJ showed higher performance in the Japanese population than those from European (pseudo
369	$R^2 = 0.709$ in European versus 0.737 in BBJ; Fig. 5a) despite the smaller sample size. As
370	suggested previously, cross-ancestry PRS showed higher performance than those from single
371	population-derived PRS (Fig. 5a and Supplementary Fig. 15a). Additionally, combining HF-
372	related phenotypes further improved the performance (Fig. 5a and Supplementary Fig. 15a).
373	Hereafter, we used the best model (model J in Fig. 5a). The risk of developing HF in individuals
374	with top PRS quintile was two times higher than that with bottom quintile (pseudo R^2 with 95%
375	CI for bottom quintile, 0.095 [0.084-0.107]; top quintile, 0.198 [0.183-0.214]; Supplementary
376	Fig. 15b).

377

It is made available under a CC-BY-NC-ND 4.0 International license .

378 Impact of HF-PRS on HF phenotypes and outcomes

The impact of HF-PRS on long-term outcomes has not been previously evaluated. Earlier 379 all-cause HF GWAS² and HFrEF/HFpEF GWAS⁵ did not develop a PRS. Although the Global 380 Biobank Meta-analysis Initiative (GBMI) developed an HF-PRS, it only assessed the predictive 381 performance and not the clinical impact³⁸. To assess the potential of the HF-PRS for clinical 382 applications, we investigated the association between the PRS and the onset age of HF in 383 individuals from our BBJ case samples (n = 10,810). We observed that the onset age decreased as 384 the PRS increased; individuals with the top tertile PRS were estimated to be approximately two 385 years younger at HF onset compared to the bottom tertile individuals (Fig. 5b). To further 386 explore the clinical utility of the HF-PRS, we assessed its impact on mortality using long-term 387 follow-up data in BBJ. We stratified individuals without HF by tertiles (low, intermediate, and 388 high groups) based on their PRS scores. The Kaplan–Meier estimates of cumulative 389 cardiovascular mortality rate were significantly increased in the high PRS group. Furthermore, 390 we demonstrated that the HF-PRS successfully stratified the risk of HF death (Fig. 5c). 391

It is made available under a CC-BY-NC-ND 4.0 International license .

392 Discussion

393	We performed a large-scale GWAS with 16,251 HF cases and subtypes in the Japanese
394	population along with cross-ancestry meta-GWAS and MTAG boosted by heart function-related
395	traits and identified 19 novel loci. Additionally, through various gene prioritization approaches,
396	we elucidated associations with clinical risk factors, cardiomyopathy, and drug targets.
397	Furthermore, analysis of various datatypes in the biobank, including clinical and long-term
398	prognosis data from biobanks, confirmed the identification of significant HF variants and the
399	clinical utility of HF-PRS described here.
400	The Japanese GWAS identified 20 genome-wide significant loci associated with HF. This
401	includes five new loci, where variants significantly prevalent in East Asians. We identified a
402	novel association in the CACNA1D loci, suggesting the involvement of functional alterations in
403	the calcium voltage-gated channel as a mechanism underlying HF. Since CACNA1D encodes the
404	pore-forming $\alpha 1$ subunit of Ca _v 1.3 voltage-gated L-type calcium channels (LTCC) and is highly
405	expressed in the sinus node and atrioventricular nodes ³⁹ . Mutations in CACNA1D have been
406	proved to cause sinoatrial node dysfunction ⁴⁰ suggesting the contribution of CACNA1D in the
407	development of HF through chronotropic incompetence.
408	Furthermore, we performed cross-ancestry meta-analyses for HF subtypes, where 58
409	genome-wide significant loci were identified, resulting in the discovery of eight new loci.
410	Among the prioritized genes based on the GWAS, EDNRA, and CACNA1D had a protective role
411	against heart failure and are drug targets for other diseases. Both EDNRA inhibitors and
412	CACNA1D inhibitors have already been reported to exacerbate HF, an observation that was
413	successfully supported by our genetic analysis. We also identified a GIP/GLP-1-agonist as a drug

It is made available under a CC-BY-NC-ND 4.0 International license .

repositioning candidate. By contrast, we genetically proved the detrimental effects of PDE3A
and CDK4/6 blockade on HF pathogenesis.

416 In these analyses, we found that common variants of the cardiomyopathy genes TTN, *NEBL*, and *BAG3* contributed to the development of HF. MTAG additionally identified that 417 common variants of MYBPC3 were one of the susceptibility loci. Among these, a TTN common 418 419 variant rs1484116 had a significant difference in the frequency and effect between Japanese and European populations. Notably, this common variant stratified individuals who went on to 420 421 develop HF into those with a high mortality rate. Additionally, while rare truncating variants in the TTN gene comprise the most common genetic subtype of dilated cardiomyopathy, accounting 422 for up to 25% of cases⁴¹, we show for the first time that the *TTN* common variant in a non-coding 423 region also causes HF. 424

Integrating cross-ancestry GWAS of interest and GWAS of related phenotypes improves predictive performance in CAD³⁷. In our HF-PRS, integrating HFrEF, HFpEF, AF, CAD, and left ventricular mass improved the performance. Moreover, we demonstrated that HF-PRS could predict HF death in subjects who had not yet been diagnosed as having HF.

Our study has several limitations. First, we did not have other large cohorts for the 429 430 replication analysis. We did not replicate Japanese-specific HF loci using other East Asian cohorts since there were no other large East Asian biobanks available with enough of these 431 432 patients. Instead, we assessed these variants with European data, showing the same effect 433 direction. As for cross-ancestry meta-analyses, we did not have a non-overlapping corresponding cohort for all-cause HF and NIHF. Hence, we used European all-cause HF data for the 434 435 replication of HFrEF and HFpEF cross-ancestry meta-analyses, showing almost the same effect 436 direction. Second, we did not perform quantitative trait-based enrichment analysis (e.g. TWAS

It is made available under a CC-BY-NC-ND 4.0 International license .

437 and splicing-TWAS) for the Japanese GWAS since there is no available molecular QTL dataset for the East Asian population. Thus, eQTL, sQTL, and other QTL datasets of the East Asian 438 population are required in future research to further clarify the genetic differences between the 439 East Asian and European populations. 440 In conclusion, our large-scale Japanese and cross-ancestry genetic analyses identified 19 441 new risk loci and provided insights into the distinct and shared genetic architecture of HF 442 between Japanese and Europeans. Multiple prioritization methods allowed us to identify 443 candidate genes involved in the pathogenesis. We also showed that the common variant of TTN 444 445 can be a prognostic marker for HF patients in the Japanese population. Furthermore, analyses of disease prediction and long-term survival demonstrated the clinical utility of our HF-PRS. These 446 data highlight the utility of HF genetics in clinical settings and provide useful evidence for the 447 implementation of genomic medicine. 448

It is made available under a CC-BY-NC-ND 4.0 International license .

450 **Online Methods**

451 **Study populations**

We included two cohorts for the Japanese-specific meta-analysis including the BBJ 1st 452 cohort and BBJ 2nd cohort from the BioBank Japan Project⁴². Further details on each cohort are 453 described in the Supplementary Note. 454 For GWAS quality control, we excluded samples with a call rate < 0.98 and related 455 individuals with pi-hat > 0.2, which is an index of relatedness based on pairwise identity-by 456 descent implemented in PLINK 2.0 (20 Aug 2018 ver.). We then excluded samples with a 457 heterozygosity rate > +4 s.d. We performed principal component analysis (PCA) using PLINK 458 2.0. and excluded outliers from the Japanese cluster. For the case samples in GWAS, we selected 459 individuals with HF diagnosed by a physician based on accepted medical practice criteria. 460 HFrEF was defined as having HF and LVEF < 40%, while HFpEF was defined as having HF 461 and LVEF > 50%. NIHF was defined as having HF without CAD. The demographic features of 462 the case-control cohort are shown in **Supplementary Table 1**. 463 464 Genotyping, imputation, and quality control 465 466 To construct a population-specific reference panel, we included 7,825 Japanese WGS samples. Each sample was aligned to the human genome assembly GRCh38 and subjected to 467 468 variant calling individually using the Illumina DRAGEN Bio-IT Platform (versions 3.4.12 and 469 3.5.7), generating gVCF files. Joint variant calling was subsequently performed with DRAGEN

470 (version 3.6.3), employing default parameters and filtering criteria. Next variant quality control

- 471 (QC) was conducted and variants from the jointly-called dataset were filtered out based on
- 472 several exclusion criteria: 1) the presence of multi-alleles; 2) singleton; 3) missing data rate >

It is made available under a CC-BY-NC-ND 4.0 International license .

473 5%; 4) Hardy-Weinberg Equilibrium (HWE) p-value $< 1 \times 10^{-6}$. After QC, VCF files were phased 474 on a whole-chromosome basis using SHAPEIT4 (version 4.2)⁴³.

GWAS subjects were genotyped using the Illumina Human OmniExpress Genotyping 475 BeadChip or a combination of Illumina HumanOmniExpress and HumanExome BeadChips 476 (Illumina, San Diego, CA). For genotype quality control (QC), we excluded variants with (i) 477 SNP call rate < 0.99, (ii) MAF < 0.01, and (iii) Hardy–Weinberg equilibrium P value $< 1.0 \times$ 478 10⁻⁶. BBJ 1st and BBJ 2nd cohorts were separately phased using SHAPEIT2 (version r837) and 479 EAGLE2 (version 2.39), respectively. Imputation was then carried out with Minimac4 (version 480 $(1.0.0)^{44}$ with a minor adjustment: variant positions in the array data, initially based on hg19, were 481 remapped to GRCh38 using BLAST based on the sequence of flanking sites. 482

483

484 **GWAS**

485 In the Japanese GWAS, association was performed by logistic regression analysis assuming an additive model with adjustment for age, age², sex, and top 10 principal components 486 (PCs) using REGENIE⁴⁵. We selected variants with Minimac4 imputation quality score of > 0.3487 and MAF \geq 0.01. The genome-wide significance threshold was defined at $P < 5.0 \times 10^{-8}$. The 488 genomic inflation factor (λ GC) was 1.044, 1.080, 1.050, and 1.083 for all-cause HF, HFrEF, 489 HFpEF, and NIHF, respectively. (Supplementary Figure. 2a). Adjacent genome-wide 490 significant SNPs were grouped into one locus if they were within 1 Mb of each other. We 491 defined a locus as follows: (1) extracted genome-wide significant variants ($P < 5.0 \times 10^{-8}$) from 492 the association result, (2) added 500 kb to both sides of these variants, and (3) merged 493 overlapping regions. If the locus did not contain coordinates with previously reported genome-494 wide significant variants (i.e., all variants with $P < 5.0 \times 10^{-8}$ in the previously reported locus), 495

It is made available under a CC-BY-NC-ND 4.0 International license .

496	the region was annotated as being novel. To identify independent association signals in the loci,
497	we conducted a stepwise conditional analysis for genome-wide significant loci defined as
498	described in the GWAS. First, we performed logistic regression conditioning on the lead variants
499	of each locus. We set a locus-wide significance at $P < 5.0 \times 10^{-6}$ and repeated this procedure
500	until none of the variants reached locus-wide significance for each locus.
501	
502	Linkage-disequilibrium score regression and heritability
503	To estimate confounding biases such as cryptic relatedness and population stratification,
504	we performed a linkage-disequilibrium score regression (LDSC) (Version 1.0.0). We selected
505	SNPs with MAF \geq 0.01 and variants within the major histocompatibility complex region were
506	excluded. For the regression, we used the East Asian LD scores provided by the authors
507	(https://github.com/bulik/ldsc/). The all-cause HF population prevalence was set at 6.5%
508	according to the Japan Medical Data Center and the Medical Data Vision datasets ⁴⁶ . Since
509	37.4%, 45.1%, and 26.6% of all-cause HF were HFrEF, HFpEF, and NIHF, we assumed
510	population prevalence was 2.4% for HFrEF, 2.9% for HFpEF, and 1.7% for NIHF ⁴⁷ .
511	
512	Cross-ancestry meta-analysis
513	All genomic coordinates were converted to GRCh37 with the liftover tool. Fixed-effect
514	meta-analyses based on inverse-variance weighting were performed for all HF phenotypes. We
515	defined genome-wide significant loci by iteratively spanning the ± 500 kb region around the most
516	significant variant and merging overlapping regions until no genome-wide significant variants

517 were detected within ± 1 Mb. A locus was categorized as "known" if the region after merging

518 was within ± 500 kb of variants for the corresponding phenotype in previous all-cause HF,

It is made available under a CC-BY-NC-ND 4.0 International license .

519 HFrEF, HFpEF, NIHF GWAS, "previously reported only in MTAG" if in previous all-cause HF MTAG results², otherwise, it was categorized as a novel. The most significant variant in each 520 locus was selected as the index variant. Cochran's O-test for heterogeneity was conducted to 521 identify loci with index variants that have different effect sizes across GWAS data sets. We 522 filtered variants with strong heterogeneity ($P_{het} < 1.0 \times 10^{-4}$) or MAF < 1%. 523 524 Multi-trait association study 525 To identify additional HF-risk loci, we used MTAG²⁰ in Europeans, including cardiac 526 527 MRI traits, which were most strongly correlated with HF. We included left ventricular mass as it was most strongly correlated with all HF phenotypes (Supplementary Figure 9a). We filtered 528 variants with MAF < 1% and defined genome-wide significant loci in the same way as trans-529 ancestry meta-analysis. 530 531 Independent follow-up of GWAS signals 532 We sought to replicate internally the HF-risk loci reaching genome-wide significance in 533 the Japanese GWAS meta-analyses within BBJ1 and BBJ2. As for genome-wide significant 534 535 variants identified in the cross-ancestry meta-analysis, we assessed EUR and EAS. As external replication of associations, we assessed significant variants identified in HFrEF or HFpEF using 536 European all-cause HF. 537 538 Genetic correlation of HF and cardiac imaging traits 539 Cross-trait LDSC was performed to estimate genetic correlation (rg) between HF and 540 541 cardiac MRI traits. LDSC is a computationally efficient method that utilizes GWAS summary

It is made available under a CC-BY-NC-ND 4.0 International license .

statistics to estimate heritability and genetic correlation between polygenic traits while

543 accounting for sample overlap.

544

545 Transcriptome-wide association study

We performed a transcriptome-wide association study (TWAS) to assess gene-HF 546 associations using FUSION⁴⁸, which estimates the association between predicted gene 547 expression levels and a phenotype of interest using summary statistics and gene expression 548 prediction models. We used precomputed prediction models of gene expression in tissues 549 550 considered to be relevant for HF with LD reference data in GTEx v8 and the summary statistics of the trans-ancestry HF-GWAS as input. Furthermore, we used the cross-tissue weights 551 generated in GTEx v8 using sparse canonical correlation analysis (sCCA) across 49 tissues 552 available on the FUSION website, including gene expression models for the first three canonical 553 vectors (sCCA1-3), which were shown to capture most of the gene expression signal. 554 Transcriptome-wide significant genes (eGenes) and the corresponding eQTLs were determined 555 using the Bonferroni correction, based on the average number of features (8,036.5 genes) tested 556 across all reference panels and correcting for the four HF phenotypes ($P < 1.55 \times 10^{-6}$). To 557 558 ensure that the observed associations did not reflect a random correlation between gene expression and non-causal variants associated with stroke, we performed a colocalization 559 analysis on the eGenes to estimate the posterior probability of a shared causal variant between 560 561 the gene expression and trait association (PP4). eGenes presenting a PP4 \ge 0.75 were considered to be significant. 562

563

564 Splicing-TWAS

It is made available under a CC-BY-NC-ND 4.0 International license .

We performed a splicing-TWAS to assess splicing-HF associations using MetaXcan. We used GTEx v8 MASHR-based models (<u>https://github.com/hakyimlab/MetaXcan</u>). The significant splicing sites were determined using the Bonferroni correction, based on the number of splicing sites multiplied by the four HF phenotypes.

569

570 Identifying protein-altering variants

To identify protein-altering variants among our genome-wide significant associations, we took the sentinel variants and their LD proxies at $r^2 \ge 0.8$ as estimated in the European ancestry subset of 1000 Genomes Project phase 3 and annotated them using the Ensembl VEP. We selected for each sentinel variant any proxies identified as having a 'high' (that is, stop-gain and stop-loss, frameshift insertion and deletion, donor and acceptor splice-site and initiator codon variants) or 'moderate' (that is, missense, in-frame insertion and deletion, splice region) consequence and recorded the gene that the variant disrupts.

578

579 Polygenic prioritization of candidate causal genes

We implemented PoPS, a similarity-based gene prioritization method designed to leverage the full genome-wide signal to nominate causal genes independent of methods utilizing GWAS data proximal to the gene (https://github.com/FinucaneLab/pops.git). Broadly, PoPS leverages polygenic enrichments of gene features including cell-type-specific gene expression, curated biological pathways, and protein-protein interaction networks to train a linear model to compute a PoPS for each gene.

586

587 Variants responsible for cardiovascular-relevant monogenic disorders

It is made available under a CC-BY-NC-ND 4.0 International license .

588	To identify genes harboring pathogenic variants responsible for HF-relevant monogenic
589	disorders, we searched the NCBI's ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/).
590	Variants were pruned to those within ± 500 kb of our HF sentinel variants; categorized as
591	'pathogenic' or 'likely pathogenic'; with a listed phenotype; and with either (i) details of the
592	evidence for pathogenicity, (ii) expert review of the gene or (iii) a gene that appears in practice
593	guidelines ⁴⁹ . We then filtered the variants that were annotated with a manually curated set of
594	cardiovascular-relevant phenotype terms, including those related to HF and HF risk factors
595	(Supplementary Tables 12, 24, and 35). Where a variant was annotated with multiple genes,
596	both genes were considered as potentially pathogenic.
597	
598	Phenotyping knock-out mice
599	Human gene symbols were mapped to gene identifiers (HGNC) and mouse ortholog
600	genes were obtained using Ensembl (www.ensembl.org). Phenotype data for single-gene knock-
601	out models were obtained from the International Mouse Phenotyping Consortium, data release
602	19.1 (www.mousephenotype.org), and from the Mouse Genome Informatics database, data from
603	July 2023 (www.informatics.jax.org). For each mouse model, reported phenotypes were grouped
604	using the mammalian phenotype ontology hierarchy into broad categories relevant to HF as
605	follows: abnormal glucose homeostasis (MP:0002078), abnormal blood coagulation
606	(MP:0002551), muscle phenotype (MP:0005369), abnormal lipoprotein level (MP:0010329),
607	abnormal catecholamine level (MP:0011479), abnormal myofibroblast differentiation
608	(MP:0012196), cardiac edema (MP:0012270), abnormal lipid metabolism (MP:0013245),
609	adipose tissue necrosis (MP:0013249), abnormal susceptibility to non-insulin-dependent diabetes
610	(MP:0020086), abnormal fibroblast physiology (MP:0020414), abnormal adipose tissue

It is made available under a CC-BY-NC-ND 4.0 International license .

noradrenaline turnover (MP:0021021), cardiac amyloidosis (MP:0021148) along with 611 phenotypes previously used in CAD analysis⁴⁹ (Supplementary Table 46). This resulted in 612 mapping from genes to phenotypes in animals (Supplementary Tables 14, 25, and 36). 613 614 **PRS** derivation and performance 615 First, we divided our dataset into three groups: (i) a discovery group to derive PRS 616 (12,335 cases and 107,333 controls), (ii) a group used for linear combination (1,837 cases and 617 11,320 controls), (iii) a test group to assess PRS performance (1,837 cases and 11,319 controls), 618 619 and (iv) a group for the survival analysis (67,991 controls) (Supplementary Fig. 14). Next, we used PRS-CS to derive each PRS from Japanese-, European-, American-, African- all-cause HF, 620 European HFrEF, HFpEF, NIHF, AF, CAD, and left ventricular mass. We used LD reference 621 panels constructed using the 1000 Genomes Project phase 3 samples according to each cohort 622 population. Subsequently, we calculated PRSs in the withheld BBJ cohorts for linear 623 combination and conducted logistic regression with L1 regularization and 10-fold cross-624

validation. Finally, we used the Japanese all-cause HF, European all-cause HF, European HFrEF,

European HFpEF, European CAD, European AF, and European left ventricular mass to construct

the HF-PRS. The performance of the PRS was measured as (1) Nagelkerke's pseudo- R^2 obtained

by modeling age, sex, the top 10 PCs, and normalized PRS and (2) the area under the curve of

629 the receiver operator curve in the same model as Nagelkerke's pseudo R^2 . Using the models

630 previously described, we calculated the PRSs and assessed their performance for the independent

631 test cohort.

632

633 Association of HF-PRS with age of HF onset

It is made available under a CC-BY-NC-ND 4.0 International license .

634	To assess the association between HF-PRS and age at HF onset, we extracted HF case
635	samples with available data on age at HF onset ($n = 10,810$, the median age of HF onset was 68
636	years of age [IQR 60-76]) and constructed a linear regression model of age at HF onset
637	including HF PRS along with sex and the top 10 PCs to estimate effects of HF-PRS on age of AF
638	onset.
639	
640	Survival analysis
641	For survival analysis, the Cox proportional hazards model was used to assess the
642	association between HF-PRS and long-term mortality. We obtained survival follow-up data with
643	the ICD-10 code for 132,737 individuals from the BBJ dataset ⁴² . The causes of death were
644	classified into three categories according to ICD-10 codes: cardiovascular death (I00-I99) and
645	HF death (I50). For HF-PRS analysis, we used a holdout survival analysis cohort
646	(Supplementary Figure 10). The median follow-up period was 8.4 years (IQR 6.8 – 9.9). The
647	Cox proportional hazards model was adjusted for sex, age, the top 10 PCs, and disease status.
648	Analyses were performed with the R package survival v.2.44, and survival curves were estimated
649	using the R package survminer v.0.4.6, with modifications.

It is made available under a CC-BY-NC-ND 4.0 International license .

651 Data availability

- 652 Summary statistics of Japanese GWAS and polygenic risk scores derived in this study
- will be publicly available at the National Bioscience Database Center
- 654 (https://humandbs.dbcls.jp/en/). The GWAS summary statistics for HF (GBMI American:
- 655 https://www.globalbiobankmeta.org/; Kadoorie: https://www.ckbiobank.org/; FinnGen NIHF:
- 656 https://console.cloud.google.com/storage/browser/_details/finngen-public-data-
- 657 <u>r9/summary_stats/</u>, R9_I9_NONISCHCARDMYOP; UKBB NIHF: https://cvd.hugeamp.org/),
- and cardiac MRI (left ventricle, right ventricle and atrium: <u>http://kp4cd.org/datasets/mi;</u> left
- 659 atrium: <u>https://zenodo.org/records/5074929</u>; left ventricular mass: https://cvd.hugeamp.org/)
- 660 traits are publicly available.
- 661

662 Code Availability

The code used in this study is available on reasonable request to the corresponding authors.

665 Acknowledgements

666 We thank the staff of BBJ for their assistance in collecting samples and clinical

- information. We thank Naoko Miyagawa, Akio Wada, and Shuji Ito for their technical
- assistance. This research was funded by the Japan Agency for Medical Research and
- 669 Development (AMED) (JP24bm1423005 to K.I, nos. JP24ek0210164, JP24tm0524004, and
- ⁶⁷⁰ JP24tm0624002 to K.I., S.N., and I.K., and nos. JP24km0405209 and JP20ek0109487 to K.
- Miyazawa, K. I, S. K., S. N., H. Akazawa, and I. K.), Japan Foundation for Applied Enzymology
- (to N.E), the Japan Society for the Promotion of Science (to N. E. and K. I.), and the Research
- Funding for Longevity Sciences from NCGG (24–15 to K.O. and K.I.). BBJ was supported by

It is made available under a CC-BY-NC-ND 4.0 International license .

- the Tailor-Made Medical Treatment Program of the Ministry of Education, Culture, Sports,
- 675 Science, and Technology (MEXT) and AMED under grant numbers JP17km0305002,
- 676 JP17km0305001, and JP24tm0624002.
- 677

678 Author Contributions

- N. E., K. I., C. T., Y. K., T. N., and I. K. conceived and designed the study. K. I, C. T., K.
- Matsuda., Y. M., and Y. K. collected and managed the BBJ sample. T. N, Y. M., and Y. K.
- performed the genotyping. N. E, K. Miyazawa, S. K, H. I., R.K., H.Y., F.T., M.F., R.O.
- performed the statistical analyses. N.E, K. I, C. T, S. K., K.T., X.L, K.O., Y. O., T.Y., Y. K.,
- T.N., K.N., H. Akazawa, P.T.E., MG.L., SM.D., BF.V, J.J., and YV.S. contributed to data
- collection, processing, analysis, and interpretation. K. I, C.T., Y K., H. Aburatani, P.T.E. and
- I.K. supervised the study. N.E. and K.I. wrote the manuscript, and many authors have providedvaluable edits.
- 687

688 **Competing interests**

689 The authors declare no competing interests associated with this manuscript.

It is made available under a CC-BY-NC-ND 4.0 International license .

691 **References:**

- 692 1. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H,
- Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K and Filippatos G.
- Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1:4-25.
- 695 2. Levin MG, Tsao NL, Singhal P, Liu C, Vy HMT, Paranjpe I, Backman JD, Bellomo TR,
- Bone WP, Biddinger KJ, Hui Q, Dikilitas O, Satterfield BA, Yang Y, Morley MP, Bradford Y,
- ⁶⁹⁷ Burke M, Reza N, Charest B, Regeneron Genetics C, Judy RL, Puckelwartz MJ, Hakonarson H,
- 698 Khan A, Kottyan LC, Kullo I, Luo Y, McNally EM, Rasmussen-Torvik LJ, Day SM, Do R,
- 699 Phillips LS, Ellinor PT, Nadkarni GN, Ritchie MD, Arany Z, Cappola TP, Margulies KB,
- Aragam KG, Haggerty CM, Joseph J, Sun YV, Voight BF and Damrauer SM. Genome-wide
- association and multi-trait analyses characterize the common genetic architecture of heart failure.
- 702 Nat Commun. 2022;13:6914.
- 3. Koyama S, Ito K, Terao C, Akiyama M, Horikoshi M, Momozawa Y, Matsunaga H, Ieki
- H, Ozaki K, Onouchi Y, Takahashi A, Nomura S, Morita H, Akazawa H, Kim C, Seo JS, Higasa
- 705 K, Iwasaki M, Yamaji T, Sawada N, Tsugane S, Koyama T, Ikezaki H, Takashima N, Tanaka K,
- Arisawa K, Kuriki K, Naito M, Wakai K, Suna S, Sakata Y, Sato H, Hori M, Sakata Y, Matsuda
- K, Murakami Y, Aburatani H, Kubo M, Matsuda F, Kamatani Y and Komuro I. Population-
- specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci
 for coronary artery disease. *Nat Genet*. 2020;52:1169-1177.
- 4. Miyazawa K, Ito K, Ito M, Zou Z, Kubota M, Nomura S, Matsunaga H, Koyama S, Ieki
- H, Akiyama M, Koike Y, Kurosawa R, Yoshida H, Ozaki K, Onouchi Y, BioBank Japan P,
- Takahashi A, Matsuda K, Murakami Y, Aburatani H, Kubo M, Momozawa Y, Terao C, Oki S,
- 713 Akazawa H, Kamatani Y and Komuro I. Cross-ancestry genome-wide analysis of atrial

It is made available under a CC-BY-NC-ND 4.0 International license .

- fibrillation unveils disease biology and enables cardioembolic risk prediction. *Nat Genet*.
- 715 2023;55:187-197.
- 5. Joseph J, Liu C, Hui Q, Aragam K, Wang Z, Charest B, Huffman JE, Keaton JM,
- Edwards TL, Demissie S, Djousse L, Casas JP, Gaziano JM, Cho K, Wilson PWF, Phillips LS,
- 718 Program VAMV, O'Donnell CJ and Sun YV. Genetic architecture of heart failure with preserved
- versus reduced ejection fraction. *Nat Commun.* 2022;13:7753.
- 6. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, Narita A, Konuma
- 721 T, Yamamoto K, Akiyama M, Ishigaki K, Suzuki A, Suzuki K, Obara W, Yamaji K, Takahashi
- 722 K, Asai S, Takahashi Y, Suzuki T, Shinozaki N, Yamaguchi H, Minami S, Murayama S,
- 723 Yoshimori K, Nagayama S, Obata D, Higashiyama M, Masumoto A, Koretsune Y, FinnGen, Ito
- 724 K, Terao C, Yamauchi T, Komuro I, Kadowaki T, Tamiya G, Yamamoto M, Nakamura Y, Kubo
- 725 M, Murakami Y, Yamamoto K, Kamatani Y, Palotie A, Rivas MA, Daly MJ, Matsuda K and
- Okada Y. A cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet*.
 2021;53:1415-1424.
- 728 7. Gorska AA, Sandmann C, Riechert E, Hofmann C, Malovrh E, Varma E, Kmietczyk V,
- 729 Olschlager J, Jurgensen L, Kamuf-Schenk V, Stroh C, Furkel J, Konstandin MH, Sticht C,
- 730 Boileau E, Dieterich C, Frey N, Katus HA, Doroudgar S and Volkers M. Muscle-specific Cand2
- is translationally upregulated by mTORC1 and promotes adverse cardiac remodeling. *EMBO Rep.* 2021;22:e52170.
- 8. de Leeuw CA, Mooij JM, Heskes T and Posthuma D. MAGMA: generalized gene-set
 analysis of GWAS data. *PLoS Comput Biol.* 2015;11:e1004219.

It is made available under a CC-BY-NC-ND 4.0 International license .

735	9. Sey NYA, Hu B, Mah W, Fauni H, McAfee JC, Rajarajan P, Brennand KJ, Akbarian S
736	and Won H. A computational tool (H-MAGMA) for improved prediction of brain-disorder risk
737	genes by incorporating brain chromatin interaction profiles. Nat Neurosci. 2020;23:583-593.
738	10. Jung I, Schmitt A, Diao Y, Lee AJ, Liu T, Yang D, Tan C, Eom J, Chan M, Chee S,
739	Chiang Z, Kim C, Masliah E, Barr CL, Li B, Kuan S, Kim D and Ren B. A compendium of
740	promoter-centered long-range chromatin interactions in the human genome. Nat Genet.
741	2019;51:1442-1449.
742	11. Pirruccello JP, Bick A, Wang M, Chaffin M, Friedman S, Yao J, Guo X, Venkatesh BA,
743	Taylor KD, Post WS, Rich S, Lima JAC, Rotter JI, Philippakis A, Lubitz SA, Ellinor PT, Khera
744	AV, Kathiresan S and Aragam KG. Analysis of cardiac magnetic resonance imaging in 36,000
745	individuals yields genetic insights into dilated cardiomyopathy. Nat Commun. 2020;11:2254.
746	12. Perrot A, Tomasov P, Villard E, Faludi R, Melacini P, Lossie J, Lohmann N, Richard P,
747	De Bortoli M, Angelini A, Varga-Szemes A, Sperling SR, Simor T, Veselka J, Ozcelik C and
748	Charron P. Mutations in NEBL encoding the cardiac Z-disk protein nebulette are associated with
749	various cardiomyopathies. Arch Med Sci. 2016;12:263-78.
750	13. Jiang YH, Jiang LY, Wang YC, Ma DF and Li X. Quercetin Attenuates Atherosclerosis
751	via Modulating Oxidized LDL-Induced Endothelial Cellular Senescence. Front Pharmacol.
752	2020;11:512.
753	14. Nock NL, Wang X, Thompson CL, Song Y, Baechle D, Raska P, Stein CM and Gray-
754	McGuire C. Defining genetic determinants of the Metabolic Syndrome in the Framingham Heart
755	Study using association and structural equation modeling methods. BMC Proc. 2009;3 Suppl
756	7:S50.
- 15. Motta M, Fasano G, Gredy S, Brinkmann J, Bonnard AA, Simsek-Kiper PO, Gulec EY,
- Essaddam L, Utine GE, Guarnetti Prandi I, Venditti M, Pantaleoni F, Radio FC, Ciolfi A, Petrini
- 759 S, Consoli F, Vignal C, Hepbasli D, Ullrich M, de Boer E, Vissers L, Gritli S, Rossi C, De Luca
- A, Ben Becher S, Gelb BD, Dallapiccola B, Lauri A, Chillemi G, Schuh K, Cave H, Zenker M
- and Tartaglia M. SPRED2 loss-of-function causes a recessive Noonan syndrome-like phenotype.
- 762 *Am J Hum Genet*. 2021;108:2112-2129.
- 16. Walters RG, Millwood IY, Lin K, Schmidt Valle D, McDonnell P, Hacker A, Avery D,
- Edris A, Fry H, Cai N, Kretzschmar WW, Ansari MA, Lyons PA, Collins R, Donnelly P, Hill M,
- Peto R, Shen H, Jin X, Nie C, Xu X, Guo Y, Yu C, Lv J, Clarke RJ, Li L, Chen Z and China
- 766 Kadoorie Biobank Collaborative G. Genotyping and population characteristics of the China
- 767 Kadoorie Biobank. Cell Genom. 2023;3:100361.
- 17. Zhou W, Kanai M, Wu KH, Rasheed H, Tsuo K, Hirbo JB, Wang Y, Bhattacharya A,
- 769 Zhao H, Namba S, Surakka I, Wolford BN, Lo Faro V, Lopera-Maya EA, Lall K, Fave MJ,
- Partanen JJ, Chapman SB, Karjalainen J, Kurki M, Maasha M, Brumpton BM, Chavan S, Chen
- TT, Daya M, Ding Y, Feng YA, Guare LA, Gignoux CR, Graham SE, Hornsby WE, Ingold N,
- Ismail SI, Johnson R, Laisk T, Lin K, Lv J, Millwood IY, Moreno-Grau S, Nam K, Palta P,
- Pandit A, Preuss MH, Saad C, Setia-Verma S, Thorsteinsdottir U, Uzunovic J, Verma A,
- Zawistowski M, Zhong X, Afifi N, Al-Dabhani KM, Al Thani A, Bradford Y, Campbell A,
- 775 Crooks K, de Bock GH, Damrauer SM, Douville NJ, Finer S, Fritsche LG, Fthenou E, Gonzalez-
- Arroyo G, Griffiths CJ, Guo Y, Hunt KA, Ioannidis A, Jansonius NM, Konuma T, Lee MTM,
- 1777 Lopez-Pineda A, Matsuda Y, Marioni RE, Moatamed B, Nava-Aguilar MA, Numakura K, Patil
- S, Rafaels N, Richmond A, Rojas-Munoz A, Shortt JA, Straub P, Tao R, Vanderwerff B,
- 779 Vernekar M, Veturi Y, Barnes KC, Boezen M, Chen Z, Chen CY, Cho J, Smith GD, Finucane

- 780 HK, Franke L, Gamazon ER, Ganna A, Gaunt TR, Ge T, Huang H, Huffman J, Katsanis N,
- 781 Koskela JT, Lajonchere C, Law MH, Li L, Lindgren CM, Loos RJF, MacGregor S, Matsuda K,
- Olsen CM, Porteous DJ, Shavit JA, Snieder H, Takano T, Trembath RC, Vonk JM, Whiteman
- 783 DC, Wicks SJ, Wijmenga C, Wright J, Zheng J, Zhou X, Awadalla P, Boehnke M, Bustamante
- 784 CD, Cox NJ, Fatumo S, Geschwind DH, Hayward C, Hveem K, Kenny EE, Lee S, Lin YF,
- 785 Mbarek H, Magi R, Martin HC, Medland SE, Okada Y, Palotie AV, Pasaniuc B, Rader DJ,
- 786 Ritchie MD, Sanna S, Smoller JW, Stefansson K, van Heel DA, Walters RG, Zollner S, Biobank
- of the A, Biobank Japan P, BioMe, BioVu, CanPath Ontario Health S, China Kadoorie Biobank
- Collaborative G, Colorado Center for Personalized M, de CG, Estonian B, FinnGen, Generation
- 789 S, Genes, Health Research T, LifeLines, Mass General Brigham B, Michigan Genomics I,
- 790 National Biobank of K, Penn Medicine B, Qatar B, Sun QS, Health S, Taiwan B, Study H,
- 791 Initiative UACH, Uganda Genome R, Biobank UK, Martin AR, Willer CJ, Daly MJ and Neale
- 792BM. Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease.
- 793 *Cell Genom.* 2022;2:100192.
- 18. Aragam KG, Chaffin M, Levinson RT, McDermott G, Choi SH, Shoemaker MB, Haas
- 795 ME, Weng LC, Lindsay ME, Smith JG, Newton-Cheh C, Roden DM, London B, Investigators
- 796 G, Wells QS, Ellinor PT, Kathiresan S, Lubitz SA and Genetic Risk Assessment of Defibrillator
- 797 Events I. Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic
- 798 Discovery. *Circulation*. 2019;139:489-501.
- 19. Asai R, Kurihara Y, Fujisawa K, Sato T, Kawamura Y, Kokubo H, Tonami K, Nishiyama
- 800 K, Uchijima Y, Miyagawa-Tomita S and Kurihara H. Endothelin receptor type A expression
- 801 defines a distinct cardiac subdomain within the heart field and is later implicated in chamber
- myocardium formation. *Development*. 2010;137:3823-33.

803	20. Turley P, Walters RK, Maghzian O, Okbay A, Lee JJ, Fontana MA, Nguyen-Viet TA,
804	Wedow R, Zacher M, Furlotte NA, and Me Research T, Social Science Genetic Association C,
805	Magnusson P, Oskarsson S, Johannesson M, Visscher PM, Laibson D, Cesarini D, Neale BM
806	and Benjamin DJ. Multi-trait analysis of genome-wide association summary statistics using
807	MTAG. Nat Genet. 2018;50:229-237.
808	21. Ahlberg G, Andreasen L, Ghouse J, Bertelsen L, Bundgaard H, Haunso S, Svendsen JH
809	and Olesen MS. Genome-wide association study identifies 18 novel loci associated with left
810	atrial volume and function. Eur Heart J. 2021;42:4523-4534.
811	22. Pirruccello JP, Di Achille P, Nauffal V, Nekoui M, Friedman SF, Klarqvist MDR,
812	Chaffin MD, Weng LC, Cunningham JW, Khurshid S, Roselli C, Lin H, Koyama S, Ito K,
813	Kamatani Y, Komuro I, BioBank Japan P, Jurgens SJ, Benjamin EJ, Batra P, Natarajan P, Ng K,
814	Hoffmann U, Lubitz SA, Ho JE, Lindsay ME, Philippakis AA and Ellinor PT. Genetic analysis
815	of right heart structure and function in 40,000 people. Nat Genet. 2022;54:792-803.
816	23. Khurshid S, Lazarte J, Pirruccello JP, Weng LC, Choi SH, Hall AW, Wang X, Friedman
817	SF, Nauffal V, Biddinger KJ, Aragam KG, Batra P, Ho JE, Philippakis AA, Ellinor PT and
818	Lubitz SA. Clinical and genetic associations of deep learning-derived cardiac magnetic
819	resonance-based left ventricular mass. Nat Commun. 2023;14:1558.
820	24. Nauffal V, Di Achille P, Klarqvist MDR, Cunningham JW, Hill MC, Pirruccello JP,
821	Weng LC, Morrill VN, Choi SH, Khurshid S, Friedman SF, Nekoui M, Roselli C, Ng K,
822	Philippakis AA, Batra P, Ellinor PT and Lubitz SA. Genetics of myocardial interstitial fibrosis in
823	the human heart and association with disease. Nat Genet. 2023;55:777-786.

It is made available under a CC-BY-NC-ND 4.0 International license .

824	25.	Kumar A.	. Ravi R.	Sivakumar RK.	Chidambaram V	. Ma	iella MG.	Sinha S.	Adamo L.
			,			,			

- Lau ES, Al'Aref SJ, Asnani A, Sharma G and Mehta JL. Prolactin Inhibition in Peripartum
- 826 Cardiomyopathy: Systematic Review and Meta-analysis. *Curr Probl Cardiol*. 2023;48:101461.
- 26. Qu X, Harmelink C and Baldwin HS. Tie2 regulates endocardial sprouting and
- myocardial trabeculation. JCI Insight. 2019;5.
- 829 27. MacGrogan D, Munch J and de la Pompa JL. Notch and interacting signalling pathways
- in cardiac development, disease, and regeneration. *Nat Rev Cardiol.* 2018;15:685-704.
- 28. Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, Pon A, Cox J, Chin
- NEL, Strawbridge SA, Garcia-Patino M, Kruger R, Sivakumaran A, Sanford S, Doshi R,
- Khetarpal N, Fatokun O, Doucet D, Zubkowski A, Rayat DY, Jackson H, Harford K, Anjum A,
- Zakir M, Wang F, Tian S, Lee B, Liigand J, Peters H, Wang RQR, Nguyen T, So D, Sharp M, da
- 835 Silva R, Gabriel C, Scantlebury J, Jasinski M, Ackerman D, Jewison T, Sajed T, Gautam V and
- Wishart DS. DrugBank 6.0: the DrugBank Knowledgebase for 2024. *Nucleic Acids Res.*
- 837 2024;52:D1265-D1275.
- 29. Chen X, Ji ZL and Chen YZ. TTD: Therapeutic Target Database. *Nucleic Acids Res.*2002;30:412-5.
- 30. Zhou Y, Zhang Y, Lian X, Li F, Wang C, Zhu F, Qiu Y and Chen Y. Therapeutic target
 database update 2022: facilitating drug discovery with enriched comparative data of targeted
 agents. *Nucleic Acids Res.* 2022;50:D1398-D1407.
- 843 31. Chaugai S, Sherpa LY, Sepehry AA, Kerman SRJ and Arima H. Effects of Long- and
- 844 Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic
- 845 Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials. J
- 846 *Cardiovasc Pharmacol Ther.* 2018;23:433-445.

It is made available under a CC-BY-NC-ND 4.0 International license .

847	32. Packer M, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, Pratt CM, Petrie
848	MC, DeMets D, Kobrin I, Roux S, Swedberg K, Investigators E and Committees. Long-Term
849	Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of
850	Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials. JACC
851	Heart Fail. 2017;5:317-326.
852	33. Fradley MG, Nguyen NHK, Madnick D, Chen Y, DeMichele A, Makhlin I, Dent S,
853	Lefebvre B, Carver J, Upshaw JN, DeRemer D, Ky B, Guha A and Gong Y. Adverse
854	Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With
855	Metastatic Breast Cancer. J Am Heart Assoc. 2023;12:e029361.
856	34. Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK,
857	Liu B, Cui X, Brown K and Investigators S Tirzepatide versus Semaglutide Once Weekly in
858	Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503-515.
859	35. Rosenstock J, Wysham C, Frias JP, Kaneko S, Lee CJ, Fernandez Lando L, Mao H, Cui
860	X, Karanikas CA and Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor
861	agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised,
862	phase 3 trial. Lancet. 2021;398:143-155.
863	36. Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ and Zoungas S.
864	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med.
865	2022;28:591-598.
866	37. Patel AP, Wang M, Ruan Y, Koyama S, Clarke SL, Yang X, Tcheandjieu C, Agrawal S,
867	Fahed AC, Ellinor PT, Genes, Health Research T, the Million Veteran P, Tsao PS, Sun YV, Cho

K, Wilson PWF, Assimes TL, van Heel DA, Butterworth AS, Aragam KG, Natarajan P and

- Khera AV. A multi-ancestry polygenic risk score improves risk prediction for coronary artery
 disease. *Nat Med.* 2023;29:1793-1803.
- 38. Wang Y, Namba S, Lopera E, Kerminen S, Tsuo K, Lall K, Kanai M, Zhou W, Wu KH,
- Fave MJ, Bhatta L, Awadalla P, Brumpton B, Deelen P, Hveem K, Lo Faro V, Magi R,
- 873 Murakami Y, Sanna S, Smoller JW, Uzunovic J, Wolford BN, Global Biobank Meta-analysis I,
- Willer C, Gamazon ER, Cox NJ, Surakka I, Okada Y, Martin AR and Hirbo J. Global Biobank
- analyses provide lessons for developing polygenic risk scores across diverse cohorts. Cell
- 876 *Genom.* 2023;3:100241.
- 877 39. Kanemaru K, Cranley J, Muraro D, Miranda AMA, Ho SY, Wilbrey-Clark A, Patrick
- 878 Pett J, Polanski K, Richardson L, Litvinukova M, Kumasaka N, Qin Y, Jablonska Z, Semprich
- 879 CI, Mach L, Dabrowska M, Richoz N, Bolt L, Mamanova L, Kapuge R, Barnett SN, Perera S,
- Talavera-Lopez C, Mulas I, Mahbubani KT, Tuck L, Wang L, Huang MM, Prete M, Pritchard S,
- Dark J, Saeb-Parsy K, Patel M, Clatworthy MR, Hubner N, Chowdhury RA, Noseda M and
- 882 Teichmann SA. Spatially resolved multiomics of human cardiac niches. *Nature*. 2023;619:801-
- 883 810.
- 40. Baig SM, Koschak A, Lieb A, Gebhart M, Dafinger C, Nurnberg G, Ali A, Ahmad I,
- Sinnegger-Brauns MJ, Brandt N, Engel J, Mangoni ME, Farooq M, Khan HU, Nurnberg P,
- 886 Striessnig J and Bolz HJ. Loss of Ca(v)1.3 (CACNA1D) function in a human channelopathy
- with bradycardia and congenital deafness. *Nat Neurosci*. 2011;14:77-84.
- 41. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, Conner L,
- 889 DePalma SR, McDonough B, Sparks E, Teodorescu DL, Cirino AL, Banner NR, Pennell DJ,
- Graw S, Merlo M, Di Lenarda A, Sinagra G, Bos JM, Ackerman MJ, Mitchell RN, Murry CE,

- Lakdawala NK, Ho CY, Barton PJ, Cook SA, Mestroni L, Seidman JG and Seidman CE.
- 892 Truncations of titin causing dilated cardiomyopathy. *N Engl J Med.* 2012;366:619-28.
- 42. Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, Ninomiya T,
- 894 Tamakoshi A, Yamagata Z, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H,
- Tanaka T, Ohnishi Y, Nakamura Y, BioBank Japan Cooperative Hospital G and Kubo M.
- 896 Overview of the BioBank Japan Project: Study design and profile. *J Epidemiol*. 2017;27:S2-S8.
- 43. Delaneau O, Zagury JF, Robinson MR, Marchini JL and Dermitzakis ET. Accurate,
- scalable and integrative haplotype estimation. *Nat Commun.* 2019;10:5436.
- 44. Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew EY, Levy
- 900 S, McGue M, Schlessinger D, Stambolian D, Loh PR, Iacono WG, Swaroop A, Scott LJ, Cucca
- 901 F, Kronenberg F, Boehnke M, Abecasis GR and Fuchsberger C. Next-generation genotype
- 902 imputation service and methods. *Nat Genet*. 2016;48:1284-1287.
- 45. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, Benner C,
- 904 O'Dushlaine C, Barber M, Boutkov B, Habegger L, Ferreira M, Baras A, Reid J, Abecasis G,
- 905 Maxwell E and Marchini J. Computationally efficient whole-genome regression for quantitative
- 906 and binary traits. *Nat Genet*. 2021;53:1097-1103.
- 46. Zhang L, Ono Y, Qiao Q and Nagai T. Trends in heart failure prevalence in Japan 2014-
- 2019: a report from healthcare administration databases. *ESC Heart Fail*. 2023;10:1996-2009.
- 47. Ide T, Kaku H, Matsushima S, Tohyama T, Enzan N, Funakoshi K, Sumita Y, Nakai M,
- 910 Nishimura K, Miyamoto Y, Tsuchihashi-Makaya M, Hatano M, Komuro I, Tsutsui H and
- 911 Investigators J. Clinical Characteristics and Outcomes of Hospitalized Patients With Heart
- 912 Failure From the Large-Scale Japanese Registry Of Acute Decompensated Heart Failure
- 913 (JROADHF). Circ J. 2021;85:1438-1450.

It is made available under a CC-BY-NC-ND 4.0 International license .

914	48.	Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, Jansen R, de Geus EJ,
-----	-----	--

- 915 Boomsma DI, Wright FA, Sullivan PF, Nikkola E, Alvarez M, Civelek M, Lusis AJ, Lehtimaki
- 916 T, Raitoharju E, Kahonen M, Seppala I, Raitakari OT, Kuusisto J, Laakso M, Price AL,
- 917 Pajukanta P and Pasaniuc B. Integrative approaches for large-scale transcriptome-wide
- 918 association studies. *Nat Genet*. 2016;48:245-52.
- 49. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M,
- 920 Hindy G, Zhou W, Grace C, Roselli C, Marston NA, Kamanu FK, Surakka I, Venegas LM,
- 921 Sherliker P, Koyama S, Ishigaki K, Asvold BO, Brown MR, Brumpton B, de Vries PS,
- 922 Giannakopoulou O, Giardoglou P, Gudbjartsson DF, Guldener U, Haider SMI, Helgadottir A,
- ⁹²³ Ibrahim M, Kastrati A, Kessler T, Kyriakou T, Konopka T, Li L, Ma L, Meitinger T, Mucha S,
- Munz M, Murgia F, Nielsen JB, Nothen MM, Pang S, Reinberger T, Schnitzler G, Smedley D,
- ⁹²⁵ Thorleifsson G, von Scheidt M, Ulirsch JC, Biobank J, Epic CVD, Arnar DO, Burtt NP,
- 926 Costanzo MC, Flannick J, Ito K, Jang DK, Kamatani Y, Khera AV, Komuro I, Kullo IJ, Lotta
- 927 LA, Nelson CP, Roberts R, Thorgeirsson G, Thorsteinsdottir U, Webb TR, Baras A, Bjorkegren
- JLM, Boerwinkle E, Dedoussis G, Holm H, Hveem K, Melander O, Morrison AC, Orho-
- Melander M, Rallidis LS, Ruusalepp A, Sabatine MS, Stefansson K, Zalloua P, Ellinor PT,
- 930 Farrall M, Danesh J, Ruff CT, Finucane HK, Hopewell JC, Clarke R, Gupta RM, Erdmann J,
- 931 Samani NJ, Schunkert H, Watkins H, Willer CJ, Deloukas P, Kathiresan S, Butterworth AS and
- 932 Consortium CAD. Discovery and systematic characterization of risk variants and genes for
- coronary artery disease in over a million participants. *Nat Genet*. 2022;54:1803-1815.

934

It is made available under a CC-BY-NC-ND 4.0 International license .

936 Figures





Fig. 1 | Overview of the study design. Flowchart of the study, which encompasses the Japanese
GWAS with the BioBank Japan, a trans-ancestry meta-analysis with large-scale European and
other population GWAS followed by the downstream analysis. GWAS, genome wide association
study; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart
failure with reduced ejection fraction; NIHF; non-ischemic heart failure; TWAS, transcriptomewide association study.





Fig. 2 | Prioritized genes. (a) The odds ratios for HF development of the independent signals in
the Japanese GWAS, cross-ancestry meta-analysis, and MTAG. The color of each point indicates
the corresponding HF phenotype. The size of each point indicates -log₁₀(P value). The shape of
each point indicates the methods of analysis. The marker inside each point indicates novelty
status. (b) Prioritized genes for each HF phenotype according to the types of analyses. *CACNA1D* was prioritized in both BBJ and cross-ancestry meta-analysis and is shown in the
"Meta-analysis" row. BBJ, BioBank Japan; HF, heart failure; HFpEF, heart failure with

- 952 preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; Meta, meta-
- analysis; MTAG, multi-trait analysis of genome-wide association study; NIHF, non-ischemic
- 954 heart failure.

It is made available under a CC-BY-NC-ND 4.0 International license .



955

Database • GO • KEGG • PI • REACTOME • WP

Fig. 3 | **Pathway analysis for each HF phenotype.** Enriched terms (FDR < 0.05) for each HF

phenotype from GO, KEGG, PI, Reactome, and WP. Up to the top 20 enriched terms in each HF

phenotype gene set are labeled. The color of the dots indicates the pathway. There was no

959 enriched pathway for HFpEF. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and

960 Genomes; PI, Pathway Interaction database; WP, Wiki Pathways.



961

Fig. 4 | Effects of common variants in cardiomyopathy genes on left ventricular function
and long-term HF mortality. (a) Minor allele frequency of lead SNPs in cardiomyopathy genes
for East Asian and European populations according to gnomAD. (b) Effect size comparison of
rs148116 (*TTN*) between BBJ and European for HFrEF. (c) Effects of lead variants in
cardiomyopathy genes on LVEF in BBJ cohorts (left panel) and UKBB cohorts (right panel).
Data are presented as estimated coefficients and their 95% confidence interval (CI). The shape of
the points in c and d indicates the HF subtypes. Red points in c and d indicate statistically

- 969 significant effects. HF, heart failure; NIHF, non-ischemic heart failure. (d) Effects of lead
- 970 variants in cardiomyopathy genes for HF mortality among HF patients (indicated as circles, ICD-
- 10 I50, 326 deaths among 8,481 individuals) and non-HF individuals (indicated as squares, ICD-
- 10 I50, 749 deaths among 121,070 individuals). (e) Cumulative incidence curve for HF death
- according to carriers of rs1484116 (*TTN*) in HF patients.

It is made available under a CC-BY-NC-ND 4.0 International license .





974

Nagelkerke's pseudo R^2 for all-cause HF case-control status in the Japanese independent cohort

977 (1,837 cases and 11,319 controls). PRS-derivation cohorts are indicated on the x-axis. (b)

Association between HF-PRS and onset age of HF. The onset age of HF in individuals with data

available (n = 10,810) is shown based on the HF-PRS tertiles. The number of individuals in each

- tertile is 3,603 to 3,604. The center line of the box plot indicates the median, the bounds
- represent the first and third quartile, and the whiskers reach to 1.5 times the interquartile range.

- 982 (c) Kaplan-Meier estimates of cumulative events from cardiovascular mortality (left) and HF
- death (right) are shown with a band of 95% CI. Individuals are classified into high (top tertile),
- 984 intermediate (middle tertile), and low PRS (bottom tertile). P values were calculated for PRS by
- 985 Cox proportional hazard analysis and the significance was set at $P = 8.3 \times 10^{-3}$ (0.05/6).

1 2 3	Genome-wide analysis of heart failure enables polygenic and monogenic prediction of heart failure risks
4	
5	
6	Table of Contents
7	Supplementary Notes 3
8	1. The SNP heritability and the liability-scale heritability
9	2. Replication of previously identified HF risk loci
10	3. Internal and external replication for novel loci found in BBJ GWAS 3
11	4. Cohorts used for cross-ancestry meta-analyses 4
12	5. Internal and external replication of cross-ancestry meta-analyses results . 5
13	6. Prioritization of rs10851802 in the cross-ancestry meta-analyses 5
14	7. Prioritized genes in MTAG 5
15	Supplementary methods 6
16	Cohort characteristics for BBJ 1 st cohort and BBJ 2 nd cohort
17	Cell type-specific heritability enrichment of disease associations
18	using stratified LD score regression7
19	Links between medication and prioritized loci
20	miRNA enrichment analysis8
21	Heritability enrichment with scDRS 8
22	Supplementary Figures9
23	Supplementary Fig. 1 Results of Japanese GWAS9
24	Supplementary Fig. 2 Validation of previously identified loci using BBJ 10
25	Supplementary Fig. 3 Comparison of allele frequencies and

It is made available under a CC-BY-NC-ND 4.0 International license .

26	allelic effects identified in Japanese GWAS 11
27	Supplementary Fig. 4 Downstream analysis of Japanese GWAS 13
28	Supplementary Fig. 5 Phenogram of genome-wide significant loci for HF
29	and its subtypes15
30	Supplementary Fig. 6 Results of the cross-ancestry meta-analysis16
31	Supplementary Fig. 7 QQ plot and comparison of allele frequencies
32	and allelic effects identified in the cross-ancestry meta-analysis 17
33	Supplementary Fig. 8 Downstream analysis of
34	cross-ancestry meta-analysis19
35	Supplementary Fig. 9 Results of multi-trait analysis of GWAS 21
36	Supplementary Fig. 10 Downstream analysis of
37	multi-trait analysis of GWAS23
38	Supplementary Fig. 11 Benn diagram for genes identified by each analysis 25
39	Supplementary Fig. 12 miRNA enrichment analysis and
40	Single-cell enrichment analysis26
41	Supplementary Fig. 13 Candidate drugs linked to disease
42	susceptibility loci for HF27
43	Supplementary Fig. 14 Analytical scheme for PRS development 28
44	Supplementary Fig. 15 PRS performance 29
45	Members of participating consortia 30
46	References

It is made available under a CC-BY-NC-ND 4.0 International license .

48 **Supplementary Notes**

49 **1. The SNP heritability and the liability-scale heritability**

- 50 The proportion of the variation in HF phenotypes (the single nucleotide polymorphism (SNP)
- heritability; h^2) was estimated to be 1.5% (standard error of the mean [s.e.m.] 0.3%) for all-cause

52 HF, 1.5% (0.3%) for HFrEF, 0.5% (0.3%) for HFpEF, and 1.1% (0.3%) for NIHF using linkage

disequilibrium (LD)-score regression (LDSC). The liability-scale h^2 was estimated at 4.8%

54 (s.e.m. 1.0%) for all-cause HF, 12.6% (2.9%) for HFrEF, 2.8% (1.7%) for HFpEF, and 3.1%

55 (1.0%) for NIHF, suggesting the heterogeneous heritability in each HF phenotype.

56

57 2. Replication of previously identified HF risk loci

58 We assessed the 47 independent variants previously reported from all-cause HF GWAS¹, 13

variants from HFrEF GWAS, one variant from HFpEF $GWAS^2$, and one variant from NIHF³ in

60 our Japanese GWAS (BBJ). Out of 47 variants identified in the previous all-cause HF GWAS,

61 34 variants or variants tagged with the lead variant existed in BBJ, 28 had the same effect

direction, and 18 were nominally significant (P < 0.05; Supplementary Fig. 2, Supplementary

Table 3). Out of 13 variants identified in the European HFrEF GWAS, 11 existed in BBJ, 10 had

64 the same effect direction, and 3 were nominally significant. The lead variant identified in the

65 European HFpEF GWAS had the same direction and was nominally significant in BBJ, and the

lead or tagged variant identified in the European NIHF GWAS did not exist in BBJ.

67

68 3. Internal and external replication for novel loci found in BBJ GWAS

69 We sought to replicate the HF-risk loci that reached genome-wide significance in individual

70 GWAS cohorts. The effect size, direction (Supplementary Fig. 3a), and allele frequency of the

It is made available under a CC-BY-NC-ND 4.0 International license .

71	identified lead variants (Supplementary Figure 3b) were strongly concordant in BBJ 1st and
72	BBJ 2 nd cohorts for all HF phenotypes (Pearson's correlation: all-cause HF 0.981; HFrEF 0.961;
73	HFpEF 0.752; NIHF 0.992). Three out of the five newly identified loci were nominally
74	significant in both BBJ 1st and BBJ 2nd cohorts (Supplementary Fig. 3a and Supplementary
75	Table 4). Out of the five newly identified loci, three loci identified in all-cause HF were found in
76	the European GWAS. rs35593046 were successfully replicated with nominal association ($P <$
77	0.05) with the same effect direction (Supplementary Fig. 3c and Supplementary Table 5). As
78	for rs6471480 and rs7075837, the same effect direction was observed in the European
79	population. rs76704104 identified in HFrEF and rs78228190 identified in HFpEF were not
80	observed in the European population according to the Genome Aggregation Database v4.0.0
81	(gnomAD) (<u>https://gnomad.broadinstitute.org/</u>).
82	
82 83	4. Cohorts used for cross-ancestry meta-analyses
82 83 84	4. Cohorts used for cross-ancestry meta-analysesCross-ancestry datasets (Supplementary Table 18) yielded 120,203 cases for all-cause HF
82 83 84 85	 4. Cohorts used for cross-ancestry meta-analyses Cross-ancestry datasets (Supplementary Table 18) yielded 120,203 cases for all-cause HF (BBJ: 16,251, EUR: 95,524, KADOORIE: 1,467, AMR: 1,170, AFR: 5,791), 23,749 cases for
82 83 84 85 86	 4. Cohorts used for cross-ancestry meta-analyses Cross-ancestry datasets (Supplementary Table 18) yielded 120,203 cases for all-cause HF (BBJ: 16,251, EUR: 95,524, KADOORIE: 1,467, AMR: 1,170, AFR: 5,791), 23,749 cases for HFrEF (BBJ 4,254, EUR: 19,495), 26,743 cases for HFpEF (BBJ: 7,154, EUR: 19,589), and
 82 83 84 85 86 87 	4. Cohorts used for cross-ancestry meta-analyses Cross-ancestry datasets (Supplementary Table 18) yielded 120,203 cases for all-cause HF (BBJ: 16,251, EUR: 95,524, KADOORIE: 1,467, AMR: 1,170, AFR: 5,791), 23,749 cases for HFrEF (BBJ 4,254, EUR: 19,495), 26,743 cases for HFpEF (BBJ: 7,154, EUR: 19,589), and 22,864 cases for NIHF (BBJ: 11,122, UKBB: 1,816, FinnGen: 9,926). The number of control
82 83 84 85 86 87 88	 4. Cohorts used for cross-ancestry meta-analyses Cross-ancestry datasets (Supplementary Table 18) yielded 120,203 cases for all-cause HF (BBJ: 16,251, EUR: 95,524, KADOORIE: 1,467, AMR: 1,170, AFR: 5,791), 23,749 cases for HFrEF (BBJ 4,254, EUR: 19,495), 26,743 cases for HFpEF (BBJ: 7,154, EUR: 19,589), and 22,864 cases for NIHF (BBJ: 11,122, UKBB: 1,816, FinnGen: 9,926). The number of control samples was 1,502,645 (BBJ: 197,577, EUR: 1,270,968, KADOORIE: 75,149, AMR: 13,217,
 82 83 84 85 86 87 88 89 	4. Cohorts used for cross-ancestry meta-analyses Cross-ancestry datasets (Supplementary Table 18) yielded 120,203 cases for all-cause HF (BBJ: 16,251, EUR: 95,524, KADOORIE: 1,467, AMR: 1,170, AFR: 5,791), 23,749 cases for HFrEF (BBJ 4,254, EUR: 19,495), 26,743 cases for HFpEF (BBJ: 7,154, EUR: 19,589), and 22,864 cases for NIHF (BBJ: 11,122, UKBB: 1,816, FinnGen: 9,926). The number of control samples was 1,502,645 (BBJ: 197,577, EUR: 1,270,968, KADOORIE: 75,149, AMR: 13,217, AFR: 20,883) for all-cause HF, 456,520 for HFrEF/HFpEF (BBJ: 197,577, EUR: 258,943), and
 82 83 84 85 86 87 88 89 90 	4. Cohorts used for cross-ancestry meta-analyses Cross-ancestry datasets (Supplementary Table 18) yielded 120,203 cases for all-cause HF (BBJ: 16,251, EUR: 95,524, KADOORIE: 1,467, AMR: 1,170, AFR: 5,791), 23,749 cases for HFrEF (BBJ 4,254, EUR: 19,495), 26,743 cases for HFpEF (BBJ: 7,154, EUR: 19,589), and 22,864 cases for NIHF (BBJ: 11,122, UKBB: 1,816, FinnGen: 9,926). The number of control samples was 1,502,645 (BBJ: 197,577, EUR: 1,270,968, KADOORIE: 75,149, AMR: 13,217, AFR: 20,883) for all-cause HF, 456,520 for HFrEF/HFpEF (BBJ: 197,577, EUR: 258,943), and 863,254 for NIHF (BBJ: 171,995, UKBB: 387,652, FinnGen: 303,607), respectively. We
 82 83 84 85 86 87 88 89 90 91 	4. Cohorts used for cross-ancestry meta-analyses Cross-ancestry datasets (Supplementary Table 18) yielded 120,203 cases for all-cause HF (BBJ: 16,251, EUR: 95,524, KADOORIE: 1,467, AMR: 1,170, AFR: 5,791), 23,749 cases for HFrEF (BBJ 4,254, EUR: 19,495), 26,743 cases for HFpEF (BBJ: 7,154, EUR: 19,589), and 22,864 cases for NIHF (BBJ: 11,122, UKBB: 1,816, FinnGen: 9,926). The number of control samples was 1,502,645 (BBJ: 197,577, EUR: 1,270,968, KADOORIE: 75,149, AMR: 13,217, AFR: 20,883) for all-cause HF, 456,520 for HFrEF/HFpEF (BBJ: 197,577, EUR: 258,943), and 863,254 for NIHF (BBJ: 171,995, UKBB: 387,652, FinnGen: 303,607), respectively. We included variants with MAF ≥ 1% and tested a total of 11,119,536 variants for all-cause HF,

93

It is made available under a CC-BY-NC-ND 4.0 International license .

94 5. Internal and external replication of cross-ancestry meta-analyses results

The effect size and direction of the identified lead variants (Supplementary Fig. 7b) 95 were concordant in East Asians and Europeans for all HF phenotypes (Pearson's correlation: all-96 cause HF 0.898; HFrEF 0.864; NIHF 0.983) except for HFpEF, for which Pearson's correlation 97 could not be calculated with significant loci < 3. 98 To replicate lead variants of HFrEF and HFpEF using independent datasets, these were 99 assessed with European all-cause HF GWAS since there were no other available HFrEF/HFpEF 100 GWAS datasets. As for all-cause HF and NIHF, there was no dataset for external replication. 101 102 Effect sizes were generally concordant with Pearson's correlation of 0.817 in HFrEF (Supplementary Figure 7d and e). The effect direction was also concordant in all of the three 103 novel loci (Supplementary Table 21). As for HFpEF, both significant variants were known HF-104 related variants. 105 106

1076. Prioritization of rs10851802 in the cross-ancestry meta-analyses

Among novel loci, we could not prioritize a gene for rs10851802. rs10851802 is linked to *GLCE* according to the Open Targets database. rs10851802 was associated with rs2415040 ($r^2 = 0.548$), which was a variant for lean mass⁴. Lean mass is associated with incident HF⁵. Although we could not prioritize a gene in this locus, this evidence suggests that this locus was one of the disease susceptibility loci. Further investigations were warranted to identify the candidate gene in this locus.

114

115 7. Prioritized genes in MTAG

It is made available under a CC-BY-NC-ND 4.0 International license .

116	BDNF prioritized by PoPS (Supplementary Table 40) harbored pathogenic variants
117	responsible for obesity (Supplementary Table 38), and its knockout showed the same
118	phenotype (Supplementary Table 39). MYBPC3 was one of the known cardiomyopathy genes
119	(Supplementary Table 14, 38 and 39), and this is the first report to show that common variants
120	of MYBPC3 were associated with HF. SLC4A7, prioritized by PoPS (Supplementary Table 40),
121	was associated with abnormal vasoconstriction (Supplementary Table 39). Considering
122	SLC4A7 splicing was enriched in fibroblasts (Supplementary Figure 10b), it suggested that
123	arterial fibroblasts contributed to HF through hypertension. Common variants in PCSK1
124	influenced blood pressure ⁶ , which was consistent with the fact that <i>PCSK1</i> was prioritized H-
125	MAGMA using the aorta Hi-C dataset (Supplementary Fig. 10c) and PCSK1 knockout showed
126	obesity and hypertension (Supplementary Table 39). PTPRJ knockout showed abnormal
127	vascular development and abnormal heart development (Supplementary Table 39). PLPP3 was
128	enriched in the fibroblasts in TWAS (Figure 10a), and its knockout caused the abnormal
129	vasculogenesis. These results were consistent with the previous report which indicated that
130	PLPP3 regions was associated with hypertension ⁷ and coronary artery disease ⁸ .
131	Among the novel loci, we could not assign a gene to rs10888955. This variant was
132	strongly associated with reticulocyte count9. Given that previous Mendelian randomization
133	analysis revealed the positive association of CAD with reticulocytes ¹⁰ , this locus could
134	contribute to HF development through CAD.
135	

136

137 Supplementary methods

138 Cohort characteristics for BBJ 1st cohort and BBJ 2nd cohort

It is made available under a CC-BY-NC-ND 4.0 International license .

139	All subjects were Japanese and were registered in the BioBank Japan (BBJ) project
140	(https://biobankjp.org/). The BBJ is a hospital-based national biobank project that collects DNA
141	and serum samples and clinical information from 12 cooperative medical institutes throughout
142	Japan (Osaka Medical Center for Cancer and Cardiovascular Diseases, Cancer Institute Hospital
143	of Japanese Foundation for Cancer Research, Juntendo University, Tokyo Metropolitan Geriatric
144	Hospital, Nippon Medical School, Nihon University School of Medicine, Iwate Medical
145	University, Tokushukai Hospitals, Shiga University of Medical Science, Fukujuji Hospital,
146	National Hospital Organization Osaka National Hospital, and Iizuka Hospital). Approximately
147	267,000 patients with any of the 47 target diseases were enrolled from 2003 to 2007, and from
148	2013 to 2018. All subjects were at least 18 years old. Informed consent was obtained from all
149	participants, and our study was approved by the relevant ethical committee at each facility.
150	
151	Cell type-specific heritability enrichment of disease associations using stratified LD score
152	regression
153	We applied stratified LD score regression (S-LDSC) ¹¹ (v1.0.1. https://github.com/bulik/ldsc) to
154	the GWAS summary statistics of the cross-ancestry meta-analysis to evaluate the contribution of
155	genetic variation in cell type-specific genes to trait heritability. Heritability enrichment per cell
156	type was considered significant at $P < 7.2 \times 10^{-5}$ (0.05/694) based on the number of cell types
157	tested (694).
158	
159	Links between medication and prioritized loci

We searched medications linked to prioritized genes using DrugBank and the Therapeutic Target
 Database. Among medications with the same pharmacological actions, we chose a representative

It is made available under a CC-BY-NC-ND 4.0 International license .

- one manually. The role of prioritized genes (e.g. protective or detrimental against HF) was
- determined based on (1) knockout mice phenotyping or (2) the direction of TWAS Z-score if
- 164 knockout mice phenotyping was not reported to be associated with HF.
- 165

166 miRNA enrichment analysis

- 167 The overall polygenic contribution of miRNA-target gene network to the traits through the
- tissue-naïve approach was estimated using MIGWAS software with default settings¹². The
- significance threshold was set at 0.0125 based on the number of HF phenotypes (0.05/4).
- 170 Candidate miRNA-gene pairs were estimated by MIGWAS with a significance threshold set at
- 171 FDR < 0.05 for miRNA and genes.
- 172

173 Heritability enrichment with scDRS

To determine which cell types in hearts were enriched for HF GWAS, we used scDRS $(v.1.0.2)^{13}$ 174 with default settings. We used MAGMA v.1.10¹⁴ to map single-nucleotide polymorphisms to 175 genes (GRCh37 genome build from the 1000 Genomes Project) using an annotation window of 176 0 kb. We used the resulting annotations and GWAS summary statistics to calculate each gene's 177 178 MAGMA z score (association with a given trait). The 1,000 disease genes used for scDRS were chosen and weighted based on their top MAGMA z scores. To determine trait association at the 179 annotated cell type resolution, we used the z scores computed from scDRS's downstream Monte 180 181 Carlo test. These Monte Carlo z scores were converted to theoretical P values using a one-sided test under a normal distribution. The significance threshold was set at $P < 2.4 \times 10^{-3}$ based on 182 Bonferroni correction (0.05/21 based on the number of cell types). 183

It is made available under a CC-BY-NC-ND 4.0 International license .



185 Supplementary Figures

Supplementary Fig. 1 | Results of Japanese GWAS. (a) Sample overlap between each HF phenotype in Japanese GWAS. (b) Miami plot for four HF phenotypes. $-\log_{10}(P \text{ value})$ on the *y*axis are shown against the genomic positions (hg19) on the *x*-axis. Association signals that reached a genome-wide significance level ($P < 5 \times 10^{-8}$) are shown in red if new loci and in blue if previously reported only in MTAG but not in GWAS. (c) QQ plot for each HF phenotype in Japanese GWAS. Two-sided *P* values were calculated using a logistic regression model. GWAS, genome-wide association study; HF, heart failure; MTAG, multi-trait analysis of GWAS.

It is made available under a CC-BY-NC-ND 4.0 International license .



194

195 Supplementary Fig. 2 | Validation of previously identified HF loci in BBJ. Comparison of

allelic effects (a) and allele frequency (b) between the previous GWAS and BBJ. Effect size with its 95% CI or allele frequency of previous GWAS are shown in the *x*-axis, and those of BBJ are

198 shown in the *y*-axis.





Supplementary Fig. 3 | Comparison of allele frequencies and allelic effects identified in
Japanese GWAS. (a and b) Comparison of allelic effects (a) and allele frequency (b) between
BBJ 1st and BBJ 2nd. Effect size with its 95%CI or allele frequency of BBJ 1st GWAS are shown
in the *x*-axis, and those of BBJ 2nd are shown in the *y*-axis. (c and d) Comparison of allelic
effects (c) and allele frequencies (d) between our Japanese GWAS (BBJ) and European GWAS.
Effect size and its 95%CI, or allele frequencies of BBJ are shown in the *x*-axis, and those of

- 207 European GWAS are shown in the y-axis. Points are shown in red if new loci and in blue if
- 208 previously reported only in MTAG but not in GWAS. CI, confidence interval; GWAS, genome-
- wide association study; HF, heart failure; MTAG, multi-trait analysis of GWAS; QQ, quantile-
- 210 quantile.
- 211



Supplementary Fig. 4 | Downstream analysis of Japanese GWAS. (a) Lead variants identified in our Japanese GWAS of each HF phenotype are searched in previously reported Japanese GWAS of cardiovascular-related phenotypes. The color indicates the Z value of the corresponding Japanese GWAS. (b and c) Lead variants identified by each HF phenotype Japanese GWAS are searched in GTEx eQTL (b) and sQTL (c). The color indicates the Z value of the corresponding eQTL or sQTL. rs6596471, which was strongly correlated with lead variant chr5:138668504:T:C ($r^2 > 0.8$) is used as proxy variant since chr5:138668504:T:C was not found

It is made available under a CC-BY-NC-ND 4.0 International license .

- in GTEx database. (d) Manhattan plots of H-MAGMA using aorta or adrenal gland Hi-C
- datasets. -log₁₀(FDR) on the *y*-axis are shown against the genomic positions (hg19) on the *x*-axis.
- 222 Genes that have not been identified in previous TWAS, proteome-wide MR, or gene analysis are
- shown in red. ** indicates novel loci, and * indicates loci previously reported only in MTAG and
- not in GWAS. eQTL, expression quantitative trait loci; GWAS, genome-wide association study;
- 225 HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure
- with reduced ejection fraction; H-MAGMA, Hi-C coupled MAGMA; LAA, left atrial
- 227 appendage; MTAG, multi-trait analysis of GWAS; NIHF; non-ischemic heart failure; sQTL,
- splicing quantitative trait loci.

It is made available under a CC-BY-NC-ND 4.0 International license .



231 Supplementary Fig. 5 | Phenogram of genome-wide significant loci for HF and its subtypes.

Indicated gene names are the prioritized gene when one gene is prioritized by our methods, the

nearest gene when multiple genes are prioritized equally, and the blank when none is prioritized

and nearest gene is RNA gene. The shapes indicate HF subtypes; circles, all-cause HF;

rectangles, HFrEF; triangles, HFpEF; and diamonds, non-ischemic HF. Colors indicate HF and

its subtypes; red, BioBank Japan (BBJ); gray, European (EUR); light green, trans-ancestry meta-

237 analysis (META); and black, multi-trait analysis of GWAS (MTAG). Cytobands and annotations

are based on GRCh37/hg19. Gene names were annotated if prioritized by at least 3 methods.

239

It is made available under a CC-BY-NC-ND 4.0 International license .



Supplementary Fig. 6 | Results of the cross-ancestry meta-analysis. Miami plot of transancestry meta-analysis. $-\log_{10}(P \text{ value})$ on the *y*-axis is shown against the genomic positions (hg19) on the *x*-axis. Association signals that reached a genome-wide significance level (P < 5 × 10⁻⁸) are shown in red if new loci and in blue if previously reported only in MTAG but not in GWAS. GWAS, genome-wide association study; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; MTAG, multitrait analysis of GWAS.



Supplementary Fig. 7 | QQ plot and comparison of allele frequencies and allelic effects
identified in the cross-ancestry meta-analysis. (a) QQ plot for each HF phenotype in the crossancestry meta-analysis. Two-sided *P* values were calculated using a logistic regression model. (b
and c) Comparison of allelic effects (b) and allele frequency (c) between East Asian GWAS and
European GWAS. Effect size with its 95%CI or allele frequency of East Asian (for all-cause HF)
or BBJ (other HF phenotypes) GWAS are shown in the *x*-axis, and those of European are shown
in the *y*-axis. (d and e) Comparison of allelic effects between the cross-ancestry meta-analysis

It is made available under a CC-BY-NC-ND 4.0 International license .

- 256 (HFrEF or HFpEF) and non-overlapping European GWAS (GBMI European all-cause HF).
- 257 Effect size with its 95% CI (d) or allele frequencies (e) of the cross-ancestry meta-analysis are
- shown in the *x*-axis, and those of European GWAS are shown in the *y*-axis. Points are shown in
- red if new loci and in blue if previously reported only in MTAG but not in GWAS. CI,
- 260 confidence interval; GWAS, genome-wide association study; HF, heart failure; HFrEF, heart
- 261 failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction;
- 262 MTAG, multi-trait analysis of GWAS; QQ, quantile-quantile.





It is made available under a CC-BY-NC-ND 4.0 International license .

- presented on the x-axis, and tissue types are on the y-axis in both (a) and (b). (c) Manhattan plots
- of MAGMA for all-cause HF, HFrEF, and non-ischemic heart failure. -log₁₀(FDR) on the y-axis
- are shown against the genomic positions (hg19) on the *x*-axis. Genes that have not been
- 275 identified in previous TWAS, proteome-wide MR, or gene analysis are shown in red. HF, heart
- 276 failure; TWAS, transcriptome-wide association studies.
It is made available under a CC-BY-NC-ND 4.0 International license .



Supplementary Fig. 9 | Results of multi-trait analysis of GWAS. (a) Genetic correlation between HF and cardiac MRI-derived parameters. Significant genetic correlations (P <0.05) are marked with an asterisk. Two-sided *P* values were calculated using linkage disequilibrium score regression. (b) Miami plot of MTAG. $-\log_{10}(P \text{ value})$ on the *y*-axis are shown against the genomic positions (hg19) on the *x*-axis. Association signals that reached a genome-wide significance level (P < 5 × 10⁻⁸) are shown in red if new loci. (c) QQ plot for each HF phenotype in MTAG. GWAS, genome-wide association study; HF, heart failure; HFpEF, heart failure with

It is made available under a CC-BY-NC-ND 4.0 International license .

- 286 preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MTAG, multi-
- trait analysis of GWAS; NIHF, non-ischemic heart failure; QQ, quantile-quantile.

It is made available under a CC-BY-NC-ND 4.0 International license .







It is made available under a CC-BY-NC-ND 4.0 International license .

- 297 on the y-axis in both (a) and (b). (c and d) Manhattan plots of MAGMA for all-cause HF or non-
- ischemic heart failure (c), and H-MAGMA using aorta Hi-C datasets in all-cause HF(d). -
- log₁₀(FDR) on the *y*-axis are shown against the genomic positions (hg19) on the *x*-axis. Genes
- that have not been identified in previous TWAS, proteome-wide MR, or gene analysis are shown
- 301 in red. HF, heart failure; TWAS, transcriptome-wide association studies.

It is made available under a CC-BY-NC-ND 4.0 International license .



303

- 304 Supplementary Fig. 11 | Benn diagram for genes identified by each analysis. BBJ, BioBank
- Japan; EUR, European; META, meta-analysis; MTAG, multi-trait analysis of GWAS.

It is made available under a CC-BY-NC-ND 4.0 International license .



307

308 Supplementary Fig. 12 | miRNA enrichment analysis and single-cell enrichment analysis.

309 (a) MIGWAS results of the four HF phenotypes. The overall contribution of miRNA-target gene

- 310 network to the traits through the tissue-naïve approach. An enrichment signal is shown by -
- $\log_{10}(P_{\text{MIGWAS}})$. (b) Heatmaps depicting each cell type-disease association for HF phenotypes.
- 312 Heatmap colors denote uncorrected *P* value of cell-type-disease association evaluated using
- 313 scDRS. Only significant associations are shown.

It is made available under a CC-BY-NC-ND 4.0 International license .



314

315 Supplementary Fig. 13 | Candidate drugs linked to disease susceptibility loci for HF. Dark

blue indicates HF subtypes; orange gene; purple medications; and brown diseases.

317

It is made available under a CC-BY-NC-ND 4.0 International license .



319



- for derivation, cross-validation, performance testing of HF-PRS in the independent test cohort,
- 322 and survival analysis for HF-PRS.

It is made available under a CC-BY-NC-ND 4.0 International license .





Supplementary Fig. 15 | PRS performance. (a) Pairwise comparison of PRS performance. 325 Distribution of the pairwise difference of Nagelkerke's pseudo- R^2 (Δ pseudo- R^2 : Pseudo R^2 score 326 $Y - Pseudo R^{2}_{Score} X$, X, and Y are found at the axis) between each pair of PRS models. The 327 distributions were obtained by bootstrapping 5.0×10^4 times. Two-sided bootstrap P values were 328 calculated by counting the number of Δ pseudo-R² \leq 0 or Δ pseudo-R² > 0 and then multiplying 329 the lower value by the minimum estimated P value $(2 * 1 / (5.0 \times 10^4) = 4 \times 10^{-5}$: two-sided). 330 The significance was set at $P = 5.0 \times 10-3$ (0.05/10). (b) PRS distribution and HF prevalence. 331 Prevalence of HF based on the HF-PRS deciles in each combination of GWAS. The number of 332 individuals in each decile is 2,631-2,632. Data are presented as medians and 95% CI. PRS. 333 polygenic risk score; CI, confidence interval. 334

It is made available under a CC-BY-NC-ND 4.0 International license .

335 Members of participating consortia

336 The Biobank Japan Project

- 337 Koichi Matsuda^{1,2}, Takayuki Morisaki^{2,3}, Yukinori Okada⁴, Yoichiro Kamatani⁵, Kaori Muto⁶,
- 338 Akiko Nagai⁶, Yoji Sagiya², Natsuhiko Kumasaka⁷, Yoichi Furukawa⁸, Yuji Yamanashi³,
- 339 Yoshinori Murakami³, Yusuke Nakamura³, Wataru Obara⁹, Ken Yamaji¹⁰, Kazuhisa
- 340 Takahashi¹¹, Satoshi Asai^{12,13}, Yasuo Takahashi¹³, Shinichi Higashiue¹⁴, Shuzo Kobayashi¹⁴,
- ³⁴¹ Hiroki Yamaguchi¹⁵, Yasunobu Nagata¹⁵, Satoshi Wakita¹⁵, Chikako Nito¹⁶, Yu-ki Iwasaki¹⁷,
- 342 Shigeo Murayama¹⁸, Kozo Yoshimori¹⁹, Yoshio Miki²⁰, Daisuke Obata²¹, Masahiko
- ³⁴³ Higashiyama²², Akihide Masumoto²³, Yoshinobu Koga²³ & Yukihiro Koretsune²⁴

344

- ³⁴⁵ ¹Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The
- 346 University of Tokyo, Tokyo, Japan.
- ²Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The
- 348 University of Tokyo, Tokyo, Japan.
- ³The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
- ⁴Department of Genome Informatics, Graduate School of Medicine, The University of Tokyo,

351 Tokyo, Japan.

- ⁵ Laboratory of Complex Trait Genomics, Graduate School of Frontier Sciences, The University
 of Tokyo, Tokyo, Japan.
- ⁶ Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo,
 Japan.
- ⁷ Division of Digital Genomics, Institute of Medical Science, The University of Tokyo, Tokyo,
 Japan.

It is made available under a CC-BY-NC-ND 4.0 International license .

- ⁸ Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo,
- 359 Tokyo, Japan.
- ⁹ Department of Urology, Iwate Medical University, Iwate, Japan.
- ¹⁰ Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of
- 362 Medicine, Tokyo, Japan.
- ¹¹ Department of Respiratory Medicine, Juntendo University Graduate School of Medicine,
- 364 Tokyo, Japan.
- ¹² Division of Pharmacology, Department of Biomedical Science, Nihon University School of
- 366 Medicine, Tokyo, Japan.
- ¹³ Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center, Nihon
- 368 University. School of Medicine, Tokyo, Japan.
- ³⁶⁹ ¹⁴ Tokushukai Group, Tokyo, Japan.
- ¹⁵ Department of Hematology, Nippon Medical School, Tokyo, Japan.
- ¹⁶Laboratory for Clinical Research, Collaborative Research Center, Nippon Medical School,
- 372 Tokyo, Japan.
- ¹⁷ Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.
- ¹⁸ Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.
- ¹⁹ Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
- ²⁰ The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
- ²¹Center for Clinical Research and Advanced Medicine, Shiga University of Medical Science,
- 378 Shiga, Japan.
- ²² Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Japan.
- 380 ²³ Iizuka Hospital, Fukuoka, Japan.

It is made available under a CC-BY-NC-ND 4.0 International license .

²⁴ National Hospital Organization Osaka National Hospital, Osaka, Japan.

It is made available under a CC-BY-NC-ND 4.0 International license .

383 **References**

- 1. Levin MG, Tsao NL, Singhal P, Liu C, Vy HMT, Paranjpe I, Backman JD, Bellomo TR,
- Bone WP, Biddinger KJ, Hui Q, Dikilitas O, Satterfield BA, Yang Y, Morley MP, Bradford Y,
- Burke M, Reza N, Charest B, Regeneron Genetics C, Judy RL, Puckelwartz MJ, Hakonarson H,
- 387 Khan A, Kottyan LC, Kullo I, Luo Y, McNally EM, Rasmussen-Torvik LJ, Day SM, Do R,
- ³⁸⁸ Phillips LS, Ellinor PT, Nadkarni GN, Ritchie MD, Arany Z, Cappola TP, Margulies KB,
- 389 Aragam KG, Haggerty CM, Joseph J, Sun YV, Voight BF and Damrauer SM. Genome-wide
- association and multi-trait analyses characterize the common genetic architecture of heart failure.
- 391 Nat Commun. 2022;13:6914.
- 392 2. Joseph J, Liu C, Hui Q, Aragam K, Wang Z, Charest B, Huffman JE, Keaton JM,
- Edwards TL, Demissie S, Djousse L, Casas JP, Gaziano JM, Cho K, Wilson PWF, Phillips LS,
- ³⁹⁴ Program VAMV, O'Donnell CJ and Sun YV. Genetic architecture of heart failure with preserved

versus reduced ejection fraction. *Nat Commun.* 2022;13:7753.

- 396 3. Aragam KG, Chaffin M, Levinson RT, McDermott G, Choi SH, Shoemaker MB, Haas
- 397 ME, Weng LC, Lindsay ME, Smith JG, Newton-Cheh C, Roden DM, London B, Investigators
- 398 G, Wells QS, Ellinor PT, Kathiresan S, Lubitz SA and Genetic Risk Assessment of Defibrillator
- 399 Events I. Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic
- 400 Discovery. *Circulation*. 2019;139:489-501.
- 401 4. Pei YF, Liu YZ, Yang XL, Zhang H, Feng GJ, Wei XT and Zhang L. The genetic
- 402 architecture of appendicular lean mass characterized by association analysis in the UK Biobank
- 403 study. *Commun Biol*. 2020;3:608.

It is made available under a CC-BY-NC-ND 4.0 International license .

404 5. Zhang L, Bartz TM, Santanasto A, Djousse L, Mukamal KJ, Forman DE, Hirsch CH,

- 405 Newman AB, Gottdiener JS and Kizer JR. Body Composition and Incident Heart Failure in
- 406 Older Adults: Results From 2 Prospective Cohorts. J Am Heart Assoc. 2022;11:e023707.
- 407 6. Gu Q, Yazdanpanah M, van Hoek M, Hofman A, Gao X, de Rooij FW and Sijbrands EJ.
- 408 Common variants in PCSK1 influence blood pressure and body mass index. *J Hum Hypertens*.
- 409 2015;29:82-6.
- 410 7. Donertas HM, Fabian DK, Valenzuela MF, Partridge L and Thornton JM. Common
- 411 genetic associations between age-related diseases. *Nat Aging*. 2021;1:400-412.
- 412 8. Koyama S, Ito K, Terao C, Akiyama M, Horikoshi M, Momozawa Y, Matsunaga H, Ieki
- 413 H, Ozaki K, Onouchi Y, Takahashi A, Nomura S, Morita H, Akazawa H, Kim C, Seo JS, Higasa
- 414 K, Iwasaki M, Yamaji T, Sawada N, Tsugane S, Koyama T, Ikezaki H, Takashima N, Tanaka K,
- 415 Arisawa K, Kuriki K, Naito M, Wakai K, Suna S, Sakata Y, Sato H, Hori M, Sakata Y, Matsuda
- 416 K, Murakami Y, Aburatani H, Kubo M, Matsuda F, Kamatani Y and Komuro I. Population-
- 417 specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci
- 418 for coronary artery disease. *Nat Genet*. 2020;52:1169-1177.
- 419 9. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, Chen MH, Raffield LM,
- 420 Tardaguila M, Huffman JE, Ritchie SC, Megy K, Ponstingl H, Penkett CJ, Albers PK, Wigdor
- 421 EM, Sakaue S, Moscati A, Manansala R, Lo KS, Qian H, Akiyama M, Bartz TM, Ben-Shlomo
- 422 Y, Beswick A, Bork-Jensen J, Bottinger EP, Brody JA, van Rooij FJA, Chitrala KN, Wilson
- 423 PWF, Choquet H, Danesh J, Di Angelantonio E, Dimou N, Ding J, Elliott P, Esko T, Evans MK,
- 424 Felix SB, Floyd JS, Broer L, Grarup N, Guo MH, Guo Q, Greinacher A, Haessler J, Hansen T,
- Howson JMM, Huang W, Jorgenson E, Kacprowski T, Kahonen M, Kamatani Y, Kanai M,
- 426 Karthikeyan S, Koskeridis F, Lange LA, Lehtimaki T, Linneberg A, Liu Y, Lyytikainen LP,

It is made available under a CC-BY-NC-ND 4.0 International license .

- 427 Manichaikul A, Matsuda K, Mohlke KL, Mononen N, Murakami Y, Nadkarni GN, Nikus K,
- 428 Pankratz N, Pedersen O, Preuss M, Psaty BM, Raitakari OT, Rich SS, Rodriguez BAT, Rosen
- 429 JD, Rotter JI, Schubert P, Spracklen CN, Surendran P, Tang H, Tardif JC, Ghanbari M, Volker
- 430 U, Volzke H, Watkins NA, Weiss S, Program VAMV, Cai N, Kundu K, Watt SB, Walter K,
- 431 Zonderman AB, Cho K, Li Y, Loos RJF, Knight JC, Georges M, Stegle O, Evangelou E, Okada
- 432 Y, Roberts DJ, Inouye M, Johnson AD, Auer PL, Astle WJ, Reiner AP, Butterworth AS,
- 433 Ouwehand WH, Lettre G, Sankaran VG and Soranzo N. The Polygenic and Monogenic Basis of
- 434 Blood Traits and Diseases. *Cell*. 2020;182:1214-1231 e11.
- 435 10. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H,
- 436 Riveros-Mckay F, Kostadima MA, Lambourne JJ, Sivapalaratnam S, Downes K, Kundu K,
- 437 Bomba L, Berentsen K, Bradley JR, Daugherty LC, Delaneau O, Freson K, Garner SF, Grassi L,
- 438 Guerrero J, Haimel M, Janssen-Megens EM, Kaan A, Kamat M, Kim B, Mandoli A, Marchini J,
- 439 Martens JHA, Meacham S, Megy K, O'Connell J, Petersen R, Sharifi N, Sheard SM, Staley JR,
- 440 Tuna S, van der Ent M, Walter K, Wang SY, Wheeler E, Wilder SP, Iotchkova V, Moore C,
- 441 Sambrook J, Stunnenberg HG, Di Angelantonio E, Kaptoge S, Kuijpers TW, Carrillo-de-Santa-
- 442 Pau E, Juan D, Rico D, Valencia A, Chen L, Ge B, Vasquez L, Kwan T, Garrido-Martin D, Watt
- 443 S, Yang Y, Guigo R, Beck S, Paul DS, Pastinen T, Bujold D, Bourque G, Frontini M, Danesh J,
- 444 Roberts DJ, Ouwehand WH, Butterworth AS and Soranzo N. The Allelic Landscape of Human
- Blood Cell Trait Variation and Links to Common Complex Disease. Cell. 2016;167:1415-1429

446 e19.

- 447 11. Finucane HK, Reshef YA, Anttila V, Slowikowski K, Gusev A, Byrnes A, Gazal S, Loh
- 448 PR, Lareau C, Shoresh N, Genovese G, Saunders A, Macosko E, Pollack S, Brainstorm C, Perry
- JRB, Buenrostro JD, Bernstein BE, Raychaudhuri S, McCarroll S, Neale BM and Price AL.

It is made available under a CC-BY-NC-ND 4.0 International license .

- Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell
 types. *Nat Genet*. 2018;50:621-629.
- 452 12. Sakaue S, Hirata J, Maeda Y, Kawakami E, Nii T, Kishikawa T, Ishigaki K, Terao C,
- 453 Suzuki K, Akiyama M, Suita N, Masuda T, Ogawa K, Yamamoto K, Saeki Y, Matsushita M,
- 454 Yoshimura M, Matsuoka H, Ikari K, Taniguchi A, Yamanaka H, Kawaji H, Lassmann T, Itoh M,
- 455 Yoshitomi H, Ito H, Ohmura K, AR RF, Hayashizaki Y, Carninci P, Kumanogoh A, Kamatani
- 456 Y, de Hoon M, Yamamoto K and Okada Y. Integration of genetics and miRNA-target gene
- 457 network identified disease biology implicated in tissue specificity. *Nucleic Acids Res.*
- 458 2018;46:11898-11909.
- 459 13. Zhang MJ, Hou K, Dey KK, Sakaue S, Jagadeesh KA, Weinand K, Taychameekiatchai
- 460 A, Rao P, Pisco AO, Zou J, Wang B, Gandal M, Raychaudhuri S, Pasaniuc B and Price AL.
- 461 Polygenic enrichment distinguishes disease associations of individual cells in single-cell RNA-
- 462 seq data. *Nat Genet*. 2022;54:1572-1580.
- 463 14. de Leeuw CA, Mooij JM, Heskes T and Posthuma D. MAGMA: generalized gene-set
- analysis of GWAS data. *PLoS Comput Biol*. 2015;11:e1004219.